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Summary 
 
 
Breast cancer is the most common malignancy in women and is estimated to account for 
more than 200,000 new cancer cases in the United States in the year 2002. It now 
represents the second leading cause of death (40,000) from cancer in women. Although 
the number of new breast cancer cases has been increasing, the death rate has been 
steadily decreasing. This trend may be due to earlier diagnosis, and/or increased survival 
resulting from the use of adjuvant therapy.  
Clinical outcome is affected by prognostic predictive factors. Prognostic factors are 
associated with either the metastatic or the growth potential of the primary tumor, while 
predictive factors are associated with the relative sensitivity and/or resistance to specific 
therapies. Routinely available prognostic indicators include tumor size, type, and grade, 
axillary lymph node status, estrogen and progesterone receptor status. Estrogen receptor 
status and progesterone receptor status also serve as predictive factors for expected 
response to hormone therapy. Many other molecular markers are being investigated for 
their clinical usefulness. One of the major molecular prognostic and predictive markers in 
breast cancer is the amplification status of the proto-oncogene ErbB2 (HER-2/ neu). 
The ErbB2 proto-oncogene is a component of a four-member family of closely related 
growth factor receptors that includes the epidermal growth factor receptor 
(ErbB1/HER1), ErbB3 (HER3), and ErbB4 (HER4). The human gene is located on 
chromosome 17q21 and encodes a 185-kDa protein with tyrosine kinase activity that is 
also known by the designation p185. Structurally, the protein has extracellular, 
transmembrane, and a cytoplasmic domain, the latter of which contains the tyrosine 
kinase domain and shares significant homology, although is distinct, from EGFR. Under 
normal circumstances, low levels of ErbB2 expression are detectable 
immunohistochemically in a variety of fetal and adult epithelial cells throughout the 
gastrointestinal, respiratory, and genitourinary tracts. Amplification of the ErbB2 proto-
oncogene or overexpression of the p185 protein, which generally correlate with each 
other, has been identified in 10% to 34% of breast cancers as well as in gastrointestinal, 
pulmonary, and genitourinary tumors. The mechanism by which overexpressed ErbB2 
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leads to a neoplastic phenotype occurs by activation of several different signaling 
pathways that lead to gene activation, ultimately resulting in cell proliferation. Although 
the mechanism of activation of ErbB2 has not been completely elucidated, it is thought to 
involve the formation of heterodimers with other members of the epidermal growth factor 
family of receptors or spontaneous homodimerization.  
This study was designed to compare the prognostic value of phosphorylated ErbB2 in 
well characterized primary breast cancer samples. Seventy primary breast cancers with a 
median of 45 months of follow-up were analyzed for quantitative levels of 
phosphorylated ErbB2 using new sensitive chemiluminescence-linked immunoassay 
(CLISA). Phosphorylated ErbB2 data were compared with clinical, histological and 
outcome variables as well as quantitative mRNA and protein expression levels of ErbB 
family members. ErbB2 – overexpressing tumors contained significantly more 
phosphorylated ErbB2, however PY1248 could be detected in some of low ErbB2 
expression tumors.  ErbB2 phosphorylation was correlated with disease free and overall 
survival and reduced estrogen receptor and progesterone receptor contents. Comparison 
of ErbB family expression on mRNA level with ErbB2 phosphorylation revealed 
significant correlation with ErbB2 and EGFR but inverse correlation with ErbB3 and 
ErbB4. Similar correlations were found also with respect to protein expression levels of 
these factors. 
We have also investigated total (pan) tyrosine, serine and threonine phosphorylated 
ErbB2 in 153 breast cancer samples by two-site CLISA assays. Serine and threonine 
phosphorylated ErbB2 could be detected only in low ErbB2 – expressing tumors, no 
serine and threonine phosphorylation was detectable in ErbB2 overexpressing tumors. As 
in case of PY1248, ErbB2 – overexpressing tumors contained significantly more tyrosine 
phosphorylated ErbB2, but ErbB2 tyrosine phosphorylation was detectable in some of 
low ErbB2 expression tumors as well.  Due to the fact that tumors we selected for this 
study were mostly aggressive tumors, it was impossible to analyze the prognostic value 
of ErbB2 phosphorylations. 
Akt1, Akt2 and Akt3 kinases are involved in the signal transduction pathway downstream 
of receptor tyrosine kinases via phosphoinosytol-3-kinase, influencing cell growth, 
proliferation and survival. Akt2 overexpression and amplification have been described in 
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breast, ovarian and pancreatic cancers. In this study we measured the quantitative 
expression levels of total phosphorylated (P-S473) Akt (Akt1/2/3) by means of a two-site 
CLISA on cytosol extracts obtained from 156 primary breast cancer tissue samples. We 
aimed to clarify the prognostic significance of activated Akt in primary breast cancer in 
association with other tumor biomarkers.  Akt phosphorylation was not associated with 
the nodal status and the ErbB2 expression. Only very high expression levels of P-Akt 
correlated with poor prognosis. More importantly, the prognostic value of P-Akt 
expression increased in ErbB2 overexpressing subset of patients. In addition, P-Akt was 
found to be associated with mRNA expression levels of several proliferation markers, 
such as thymidylate synthase, thymidine kinase 1, survivin, topoisomerase II alpha and 
transcription factor E2F, measured by quantitative real-time PCR (Q-RT-PCR). 
Shc adapter/docking proteins are an important component of receptor tyrosine kinase 
signaling pathways because they are involved in transducing the activation signals from 
receptor or cytoplasmic tyrosine kinases to downstream signaling cascades. At least three 
genes, shcA, shcB, and shcC, are known to encode Shc proteins. ShcA has been found to 
be phosphorylated rapidly and efficiently by all tyrosine kinases tested to date. These 
phosphorylation sites have been mapped to Y339, Y240, and Y317. In addition to 
tyrosine phosphorylation, ShcA can also be phosphorylated at serine/threonine residues. 
We have investigated pan- tyrosine, serine and threonine phosphorylated ShcA in 153 
breast cancer samples by two-site CLISA assays.  P-ShcA was found to be weekly 
associated with PT ErbB2 levels and weekly inversely correlated with P-Akt levels. A 
very good correlation was found between PS ShcA and PY SchA. 
Since it was the same collective of tumors, as the one used for ErbB2 pan-S, T and Y 
phosphorylation assessment, it was also impossible to analyze the prognostic value of 
phospho-SchA. 
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1. Introduction 
 
1.1. Breast cancer. 
1.1.1. Epidemiology. Breast cancer is the most predominant tumor among women in 
Western countries. The incidence rate is 70-100 cases per 100,000 women a year and the 
mortality rate 20-30 deaths per 100,000 women a year in Western countries and up to 5 
fold less in Eastern Asia and Africa (1, 2). There were more than 200,000 estimated new 
cases in the United States alone, in 2002 and 40,000 estimated breast cancer deaths (3). 
Recognized risk factors for breast cancer are age, increased hormone exposure and 
genetic predisposition. Brest cancer is age-dependent, e.g. incidence in North America 
and Europe is about 2.5% by the age of 55, 5% by the age of 65 and 7.5% by the age of 
75(2). Increased hormone exposure, such as early menarche, late menopause, oral 
contraceptics, hormonal therapy together with alcohol consumption and obesity is 
associated with increased risk. Breast feeding, early first pregnancy and physical exercise 
on the other hand are associated with a reduced risk (1, 2). The majority of breast cancers 
arise sporadically. However, family history is responsible for about 2-5% of breast 
cancers.  Genes involved in hereditary forms of breast cancer include BRCA1, BRCA2, 
P53, STK11/LKB1, PTEN and ATM (1, 2). 
 
1.1.2. Biology of breast cancer. The mammary gland is a highly differentiated organ that 
is responsible for providing nutrition to the progeny. Mammary development starts 
during embryogenesis; in humans, males and females have a similar rudimentary 
mammary gland at birth. Later mammary development is initiated with the beginning of 
female puberty and is dependent on the high levels of estrogen produced by the ovary, as 
well as levels of progesterone. After puberty, the mammary gland undergoes cycles of 
growth and involution, regulated by the menstrual cycle, cycles of pregnancy and 
lactation. Histologically, the mammary gland consists of a rudimentary branching duct 
system lying in a fat pad (Fig. 1). Post-pubertal development results in cyclical increases 
in ductal branching, resulting in a ductal tree that fills the fat pad. During pregnancy, 
further branching and end-bud development lead to an appearance that is like bunches of 
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“grapes”. After weaning, mammary-gland regression to a pre-pregnancy like state is 
manifested by apoptotic processes. The ductal structure consists of a continuous layer of 
epithelial cells responsible for milk synthesis and release into the lumen. A second layer 
of myoepithelial cells contacts the basement membrane. The two cell layers, together 
with fibroblasts surrounding, form the basis of the ducts (4, 5). Epithelial cells are sites of 
estradiol action in the breast, according to immunohistochemical analysis demonstrating 
that the epithelial cells estrogen receptor (ER) (6). According to the literature the luminal 
epithelial cells that are responsible for most breast tumors. The pathway to breast cancer 
development is not clear. There is some evidence, although inconclusive, to indicate that 
it might begin with hyperproliferation of the epithelial cells, progressing through a 
preneoplastic phase called ductal carcinoma in situ (DCIS), which is bounded by the 
basement membrane, to invasive breast cancer, in which the basement membrane has 
been breached. About 15–25% of epithelial cells are ER-positive in the normal resting 
breast, although the number of ER-positive cells changes throughout the menstrual cycle. 
Interestingly, estrogen stimulated proliferation occurs in ER-negative cells that surround 
the ER-positive luminal epithelial cells (7, 8). This has led to the suggestion that ER-
positive epithelial cells promote proliferation of surrounding ER-negative cells, probably 
through secretion of paracrine factors. By contrast, proliferation of ER positive epithelial 
cells in breast tumors is estrogen regulated in the majority of cases. The sequence of 
events that enable ER-positive cells to be transformed from nondividing cells to a state in 
which their proliferation is estradiol dependent is at present unclear. 
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Figure 1.  Anatomy of the human mammary gland. Each mammary gland contains 15–20 lobes, each lobe 
containing branched ducts that drain into the nipple (Nat Rev Cancer. 2002 Feb;2(2):101-12). 
 
 There is considerable evidence that links increased breast cancer risk with prolonged 
exposure to estrogens. This includes the increased risk associated with early menarche, 
late first full-term pregnancy and late menopause. Oral contraceptives and estrogen-
replacement therapy have also been implicated in breast cancer risk. In addition, dietary 
and environmental agents that can act as estrogens have been linked to breast cancer risk, 
although their true involvement in breast cancer remains to be established (9, 10). It is 
possible that the breast-cancer-promoting effects of estrogens arise simply from their 
proliferative effects on the breast. It is definitely clear that in large amount of cases 
estradiol promotes breast cancer progression by stimulating malignant cell proliferation. 
This is further confirmed by the apparent correlation between ER positivity in breast 
tumors and their response to endocrine therapy. Moreover, ER expression in benign 
breast epithelium is higher in patients with breast cancer than it is in women who do not 
have breast cancer (11), demonstrating that the ER is involved in early events in breast 
cancer. This might reflect deregulated control of ER expression in preneoplastic breast 
cancer cells, although the primary mechanisms are not defined. Nevertheless, even 
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though only 15–25% of normal breast epithelial cells are ER-positive, two-thirds of 
breast cancers are ER-positive and approx. 50% of these respond to endocrine therapy 
(12). 
 
1.1.3. Diagnosis and treatment. The mammography, ultrasound, fine needle aspirations, 
needle (core) biopsies, blood (serum) tests and excision biopsies may be used in the 
diagnosis of cancer of the breast (13-15). In addition to detecting breast cancer, or 
confirming the initial diagnosis, these tests are also useful in showing the extent (stage 
and grade) of the cancer. The stage of a cancer is a term used to describe its size and 
whether it has spread beyond its original site (16-17). Knowing the extent of the cancer 
helps to decide on the most appropriate treatment modalities. A commonly used staging 
system is described below: 
Ductal carcinoma in situ (DCIS): DCIS is when the breast cancer cells are completely 
contained within the breast ducts, and have not spread into the surrounding breast tissue. 
This may also be referred to as non-invasive or intraductal cancer, as the cancer cells 
have not yet spread into the surrounding breast tissue and so usually have not spread into 
any other part of the body. DCIS is almost always completely curable with treatment. 
Lobular carcinoma in situ (LCIS) means that cell changes are found in the lining of the 
lobules of the breast. It can be present in both breasts. It is also referred to as non-
invasive cancer as it has not spread into the surrounding breast tissue.  
Invasive breast cancer is divided into 4 stages, from small and localized (stage 1) to 
metastatic cancer (stage 4). Stage 1 tumors: these measure less than two centimeters. The 
lymph glands in the armpit are not affected and there are no signs that the cancer has 
spread elsewhere in the body. Stage 2 tumors: they measure between two and five 
centimeters, or the lymph glands in the armpit are affected, or both. However, there are 
no signs that the cancer has spread further. Stage 3 tumors: these are larger than five 
centimeters and may be attached to surrounding structures such as the muscle or skin. 
The lymph glands are usually affected, but there are no signs that the cancer has spread 
beyond the breast or the lymph glands in the armpit. Stage 4 tumors: these are of any 
size, but the lymph glands are usually affected and the cancer has spread to other parts of 
the body.  
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Grading refers to the appearance of the malignant cells, the differentiation status (18). 
The grade gives an idea of how rapidly the cancer may develop. There are three grades:  
1. grade 1 (low grade),  
2. grade 2 (moderate grade) and  
3. grade 3 (high grade).  
Low grade means that the cancer cells look differentiated, like the normal cells of the 
breast. They are usually slowly proliferating and are less likely to spread. In high grade 
tumors the cells look undifferentiated. They are likely to proliferate faster and are more 
likely to spread.  
The treatment of breast cancer depends on several factors, such as: the stage of the 
disease, age of the patient, menopausal status, the size of the tumor, the grade, whether 
they express receptors for ER and/or PgR, or other proteins such as ErbB2.  
In the earliest stages surgery may be all that is needed, but surgery is often followed by 
radiotherapy to the remaining breast tissue to make sure that any remaining tumor cells 
are destroyed, particularly if only part of the breast has been removed.  
Because there is a risk of cancer cells having escaped and being present elsewhere in the 
body, additional drug treatment (adjuvant therapy) might be necessary. Adjuvant therapy 
may consist of hormonal therapy or chemotherapy or both. 
If the cancer has spread, it is usually treated with drugs (hormonal therapy, chemotherapy 
or monoclonal antibody therapy). Whether hormonal therapies or chemotherapy are used 
will depend on the organ that the cancer has metastasized to, how much time has passed 
since the original surgery and whether or not the cancer cells have receptors for particular 
hormones or proteins on their surface. Several different hormonal therapies and many 
different types of chemotherapies can be used.  
Chemotherapies or hormonal therapies are sometimes used to shrink a large breast cancer 
before surgery. When the treatments are given before surgery it is known as neo-adjuvant 
therapy. 
Surgery. Several types of surgery are performed in order to remove breast tumors, such 
as: lumpectomy (wide local excision), quadrantectomy (segmental excision) and 
mastectomy (19).  
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For many patients a mastectomy may not be necessary. It is now often possible to just 
remove the area of cancer and some of the healthy surrounding tissue, and then give 
radiotherapy to the remaining breast tissue. This is known as breast conserving therapy. 
Research has shown that in early breast cancer, lumpectomy followed by radiotherapy is 
as effective at curing the cancer as mastectomy (19).  
As part of any surgery for breast cancer the surgeon will usually remove lymph glands 
from under an arm on the same side of the body. The lymph glands are examined to 
check whether any cancer cells have spread into them from the breast. 
Radiotherapy is most often used after surgery for breast cancer, but is sometimes used 
before, or instead of, surgery. Two main types of radiotherapy are used to treat breast 
cancer: external radiotherapy and internal radiotherapy.  
If part of the breast has been removed (lumpectomy or quadrantectomy), radiotherapy is 
usually given to the remaining breast tissue to reduce the risk of recurrence (19). The aim 
is to make sure that any remaining cancer cells are destroyed. 
If all the lymph glands have been removed from under the arm radiotherapy to the armpit 
is not usually needed. If a few lymph glands have been removed and these contained 
cancer cells, or if no lymph glands have been removed, radiotherapy may be given to the 
armpit to treat the lymph glands.  
Chemotherapy is the use of cytotoxic drugs to destroy cancer cells. Chemotherapy drugs 
are sometimes given as tablets or, more usually, intravenously. Chemotherapy is given as 
a course of treatment, which may last for less than one day or for a few days. This is 
followed by a rest period of a few weeks, which allows patients body to recover from any 
side effects of the treatment. The number of courses patient have will depend on the type 
of cancer she has and how well tumor is responding to the drugs. Side effects of 
chemotherapy includes: anemia, nausea and vomiting, hair loss, lowered resistance to 
infections, and diarrhea. Anthracyclines (doxorubicin, epirubicin), taxanes (paclitaxel, 
docetaxel), cyclophosphamide, 5-fluorouracil and methotrexate are the most commonly 
used chemotherapeutic agents used in breast cancer (20). Combinations of these agents 
have been used routinely for breast cancer treatment, most well known of which is, so 
called, “classical” CMF (cyclophosphamide, methotrexate and 5-fluorouracil) (21).  
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Hormonal therapies can slow or stop the proliferation of breast cancer cells by either 
altering the levels of estrogens which are naturally produced in the body, or preventing 
the hormones from being used by the cancer cells. There are many different types of 
hormonal therapy and they work in slightly different ways, so sometimes two different 
types of hormonal therapy may be given together. Hormonal therapy may also be given 
in combination with chemotherapy.  
Most commonly hormonal therapies are: Anti-estrogen agents,  Agents that reduce 
estrogen production, Progestogens, Pituitary down-regulators, and ovarian ablation).  
Anti-estrogen agents work by preventing estrogen in the body from activating estrogen 
receptor and therefore inducing proliferation of tumor cells. Tamoxifen is the most 
commonly used hormonal therapy for breast cancer (22) and may be given in 
combination with other types of hormonal therapies known as aromatase inhibitors. The 
side effects which may be experienced include hot flushes and sweats, a tendency to put 
on weight, etc, but these side effects are usually mild. Rarely, it is possible for tamoxifen 
to cause an endometrial cancer Tamoxifen is commonly taken after surgery and for 
metastatic cancer, but if it is not effective in controlling the cancer some of the other 
types of hormonal therapy may be used. A drug called toremifene (Fareston) which 
works in a similar way to tamoxifen is occasionally used (22). Research and early tests 
suggest that it may carry less risk of endometrial cancer than tamoxifen, and it may be 
less likely to cause hot flushes and sweats. However, the long-term effects are not yet 
known. At the moment, toremifene is only given to postmenopausal women.  
A group of agents called aromatase inhibitors work by blocking the production of 
estrogen in fatty tissues, in postmenopausal women. The commonly used aromatase 
inhibitors are anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin) and 
formestane (Lentaron). They generally do not cause many side effects, although they can 
cause hot flushes, feelings of nausea and joint pains. They are now sometimes used 
instead of tamoxifen as the first hormonal therapy (first-line treatment) in 
postmenopausal women with metastatic breast cancer (23).  
 Artificial progesterone derivatives (known as progestogens) are stronger than natural 
progesterone. Progestogens such as megestrol acetate (Megace) and 
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medroxyprogesterone acetate (Farlutal, Provera) can be used if a hormonal therapy such 
as tamoxifen is no more effective. Progestogens generally cause few side effects (24).  
Agents known as pituitary down-regulators, or LHRH analogues, reduce the production 
of estrogen-stimulating hormones by the brain, which results in a lowering of the level of 
estrogen in the body. This has the same effect as removing the ovaries or giving them 
radiotherapy, but is potentially reversible. As goserilin decreases the amount of estrogen 
circulating in the blood, it can also be an effective treatment for premenopausal women 
with metastatic breast cancer. Goserilin (Zoladex) only works for women with ER 
positive breast cancer. As goserelin brings on a temporary menopause, many of its side 
effects are similar to those of the menopause (25). 
For premenopausal women, removing the ovaries (which reduces the level of estrogen in 
the body) can reduce the chance of the cancer coming back following surgery, or can 
slow the growth of cancer cells if they have already spread beyond the breast. The ovaries 
can be removed by a surgery, or stopped from working by giving a low dose of 
radiotherapy to the area (26). Unfortunately, removing the ovaries does bring on an early 
menopause which can be distressing, especially for a woman who was hoping to have 
children or complete her family.  
Trastuzumab (Herceptin). ErbB2 (HER2/Neu) is amplified and overexpressed in 10-30% 
of breast cancers. Its amplification and overexpression have been associated with poor 
prognosis or response to anticancer therapies. Therapy based on a humanized monoclonal 
anti-ErbB2 antibody (trastuzumab/Herceptin™) has been beneficial in metastatic 
patients. Trastuzumab is the first monoclonal antibody with efficacy in breast cancer and 
the first oncogene-targeted therapy to yield a significant survival advantage in this 
disease. First-line trastuzumab in combination with chemotherapy resulted in a 25% 
improvement in overall survival compared with chemotherapy alone (27).  
1.1.4. Biomarkers. Considerable efforts have been made to subdivide patient populations 
into groups that behave differently, so that therapy can be applied more efficiently. 
Already the early efforts of observation that outcomes were related to clinical cancer size 
and the presence or absence of pathologically involved lymph nodes, led to what is now 
commonly designated as “staging,” which has now become highly codified within an 
internationally coordinated effort (17). These efforts only partially separate patients into 
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subgroups with different biological behaviors. In the context of the development of 
molecular biology and biochemistry over the last decades laboratory and clinical 
scientists have studied a series of biomarkers. Hundreds of these putative markers have 
been reported, yet very few have actually achieved common clinical use. In part, this lack 
of progress is a consequence of the astonishing biological diversity of the disease. On the 
other hand, much of the perplexity and controversy in the field arises from poorly 
designed and analyzed clinical studies.  
Currently used biomarkers could be grouped into risk assessment markers, prognostic 
markers and predictive markers. 
Risk assessment markers. Roughly, 5-10% of breast cancers are caused by the inheritance 
of a germline mutation in a cancer predisposing gene. The most important of these genes 
are BRCA1 and BRCA2. Early data from highly selected families showed that women 
who carry either a BRCA1 or BRCA2 gene had an 80 to 85% lifetime risk of developing 
breast cancer (28). By testing for mutations in BRCA1 and 2 genes in high risk families, 
it is possible to identify individuals who are at increased risk of developing breast cancer. 
Identification of these subjects has the potential to result in early diagnosis and possibly 
prevention. However, genetic testing may also result in medical, psychological and other 
personal risks that must be addressed in the context of informed consent.  
Prognostic markers can be defined as factors which correlate with patient outcome. If 
possible, these markers should be evaluated in the absence of adjuvant therapy. In breast 
cancer, prognostic factors are most useful in identifying patients whose outcome is so 
favorable that adjuvant systemic therapy is unnecessary. Prognostic indicators can also 
help in identifying patients whose prognosis is so poor with conventional approaches as 
to merit importance of more aggressive therapies. The traditional factors for assessing 
prognosis in breast cancer include tumor size, tumor grade and nodal status (29). Lymph 
node status is the most widely used, however, it has several disadvantages. Firstly, it 
requires major surgery. Major surgery does not result in enhanced survival compared to 
conservative surgery combined with radiotherapy. Another major disadvantage of nodal 
status for determining prognosis is that in the node-negative subgroup of patients, no 
reliable marker exists. With the development of mammographic screening, approximately 
two thirds of newly diagnosed breast cancer patients are node-negative. Approximately 
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70% of these patients are cured of breast cancer by surgery while the remaining 30% 
develop relapse within 10 years of diagnosis. Thus, new markers are urgently required 
which will differentiate the majority of node-negative breast cancer patients cured by 
surgery from the minority which develop relapse. Research in recent years has identified 
a large number of potential biologic prognostic markers for breast cancer (Table 1), of 
which, urokinase plasminogen activator (uPA) and its inhibitor PA1–1 are perhaps the 
most promising. More than 20 independent groups have reported that high levels of uPA 
predict unfavorable outcome in patients with breast cancer (30). In most of these studies 
the prognostic information supplied by uPA was independent of the traditional factors 
such as size, grade and nodal status. Furthermore, several different studies found uPA 
prognostic in node-negative patients. Paradoxically, high levels of PAI-1 have also been 
shown to predict poor outcome in breast cancer including the subgroup with node-
negative disease. The prognostic impact of uPA/PA1–1 in node-negative patients was 
confirmed in a large prospective randomized trial, which provided the highest level of 
evidence (Level 1) for demonstrating clinical value for these cancer markers (31). 
Recently, pooled analysis of the EORTC-RBG datasets confirmed the strong and 
independent prognostic value of uPA and PAI-1 in primary breast cancer (32). 
A predictive marker can be defined as a factor which predicts response or resistance to a 
specific therapy. The most widely used predictive marker in oncology is the estrogen 
receptor (ER) for selecting hormone responsive breast cancers (33). Although originally 
introduced to predict response to endocrine ablative therapy for patients with advanced 
breast cancer, the ER is now more widely used to select patients with early breast cancer 
likely to respond to the antiestrogen, tamoxifen. In a recent meta-analysis involving over 
37,000 women, ER-positive patients were 7-times less likely to develop recurrent disease 
than ER-negative patients after at least 5 yr of adjuvant tamoxifen treatment (12). Assay 
of the progesterone receptor (PgR) may also help in selecting hormone-responsive breast 
cancers (33). Early work showed that patients with advanced breast cancer were more 
likely to respond to hormone therapy if their primary cancer expressed both ER and PR 
compared to those tumors containing ER but lacking PgR. Knowledge of PR status does 
not however, appear to enhance the predictive ability of ER in the adjuvant setting. 
Recent data suggests that ErbB 2 (also known as HER2 or neu) may also be a useful 
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predictive marker in breast cancer. Preliminary findings suggest that overexpression of 
ErbB2 can select for resistance to hormone therapy, resistance to CMF 
(cyclophosphamide, methotrexate, 5-fluorouracil) adjuvant chemotherapy, sensitivity to 
doxorubicin-based adjuvant chemotherapy and response to the therapeutic antibody, 
Herceptin (34).  
 
1.2. Signaling by Receptor Tyrosine Kinases and EGFR family. 
1.2.1. Structure and function. Receptor tyrosine kinases (RTK) are type I membrane 
proteins, having their N- termini outside the cell and single transmembrane domain. N 
terminus starts with a signal peptide followed by an extracellular domain. Extracellular 
domain of RTKs is the most distinctive domain, which is composed of various 
recognizable sequence motifs and a pattern of Cys residues. Transmembrane domain is 
followed by a juxtamembrane region, which precedes the catalytic domain. The catalytic 
domain is about 250 residues long and is related to that of cytoplasmic PTKs. (35). The C 
terminal region varies from several up to 200 residues (Fig. 2). 
 
Figure 2.  The schematic organization  of receptor tyrosine kinase domains. N terminus is composed of an 
extracellular domain. Transmembrane domain is followed by a juxtamembrane region, which precedes the 
catalytic kinase domain. The length of C terminal region, following kinase domain, differs in various 
RTKs. 
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 Within the catalytic domains of various RTKs, sequence similarity ranges from 32 
to 95%. Alignment of kinase catalytic domains revealed there are 14 residues conserved 
in all protein kinases and several more which are found only in tyrosine kinases (36, 37). 
The structure of kinase domain is composed of two lobes. Mg2+/ATP and the protein 
substrate are brought together in the cleft, which allows phophotransfer to be catalyzed. 
The N-terminal lobe is responsible for a Mg2+/ATP binding. The responsible domain is 
the GXGXXG (21aa) K1030 (in human insulin receptor tyrosine kinase). The glycine 
fold holds the phosphate moieties of the nucleotide and the lysine residue, which is 
required for ATP binding. Further towards the C terminus another residue conserved in 
all protein kinases is E1047, which forms a salt bridge to K1030. In the other lobe, 
HRDLAARN (1130-1137) forms the catalytic loop. The Asp is believed to be the 
catalytic base. The aspartate of DGF (1150-1152) functions in the chelation of Mg2+. 
E1179 and R1253 are thought to form ion bridges that stabilize the two lobes, and D1191 
stabilizes the catalytic loop. (37, 38) 
 RTKs are known to function as receptors for growth (EGFR, PDGFR, FGFR), 
differentiation (MCF-R, NGFR) or metabolic (insulin receptor) factors. The functions of 
RTKs depend on several conditions, such as the cell specific expression of receptors as 
well as the availability of ligands and intracellular signaling molecules. Expression of 
almost all RTKs is restricted to specific cell types in the organism. This expression 
pattern depends on the character of the regulatory elements in the RTK gene promoter 
and enhancer. The function of RTK, expressed in particular cell is dictated by the ligands 
that bind the extracellular domain. It is also evident that the cell type in which the RTK is 
expressed affects the cellular response. The reason for this could be differences of 
substrates available, the strength of the signal and responses of cells to activation of the 
same pathway. On the other hand, different RTKs expressed in the same cell can evoke 
different responses through different signaling pathways. 
1.2.2. Signaling. Signal transduction is initiated by ligand binding to the receptor. After 
ligand binding, the receptor dimerizes. Different ligands could use different approaches 
to induce active dimer. Some growth factors are dimers (VEGF, PDGF) and provide the 
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simplest mechanism for receptor dimersisation (39), others are monomers and use more 
sophisticated mechanisms. FGF family ligands cooperate with accessory molecule 
heparin sulfate proteoglycan to activate FGF receptor dimers (40). Other ligands are 
thought to stabilize preexisting dimers. (41) Receptor dimerisation leads to trans-
autophosphorylation. Dimerisation of extracellular domains leads to juxtaposition of the 
cytoplasmic tails, which leads to more efficient phosphorylation of tyrosines in the 
activation loop of the receptor. (42). Consequent to tyrosine phosphorylation, the 
activation loop adopts an “open” conformation that grants access to ATP and substrates, 
and enables phosphotransfer from MgATP to tyrosines on the receptor itself and on 
intracellular proteins involved in signal transduction. (38). The phosphorylated dimer 
recruits substrates that have an increased affinity for the phosphorylated tyrosine 
residues. Most tyrosine autophosphorylation sites are located in noncatalytic regions of 
the receptor molecule. These sites function as binding sites for SH2 (Src homology 2) or 
PTB (phosphotyrosine binding) domains of a number of signaling proteins (43) (Fig. 3). 
SH2 domains recognize distinct amino acid sequences determined by 1-6 residues C-
terminal to the PY moiety (44), on the either hand PTB domains recognize PY within 
context of specific sequences 3-5 residues to its N terminus (45).  
A big class of SH2 domain–containing proteins has intrinsic enzymatic activities such as 
PTK activity (Src kinases), phospholipase activity (PLCgamma), or Ras-GAP. Another 
class of proteins contains only SH2 and other modular domains. These adaptor proteins 
(Grb2, Nck, and Shc) apply their modular domains to mediate interactions of different 
proteins involved in signal transduction. For example, the adaptor protein Grb2 interacts 
with activated RTKs by its SH2 domain and recruits the guanine nucleotide releasing 
factor Sos close to its target protein Ras and therefore links the receptor to the 
Ras/MAPK pathway (46). 
The binding of SH2 or PTB domain-containing proteins to phosphorylated RTKs can 
affect their activity in three ways: by membrane translocation, by the change of 
conformation or by tyrosine phosphorylation. Good example of activation by 
translocation to membrane is PI3K activation, while activation of Src family of PTKs is a 
classical example of activation by conformational change (see below). PLCgamma 
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activation requires tyrosine phosphorylation as well as membrane translocation (see 
below), suggesting that three ways of activation are by no means mutually exclusive. 
During the last decade, analyses of the different signaling cascades induced by RTKs let 
to the recognition of Ras/MAPK (47, 48), PI3K/Akt, PLCgamma/PKC (49, 50), and Src 
family PTKs (51) pathways as major downstream mediators of the RTK signaling. 
Several pieces of evidence suggest JAK/STAT pathway to play a very important role 
mediating RTK signaling as well (52, 53).  
 
 
 
 
Figure 3.  Authophosphorylation sites and binding of SH2 domain-containing signaling molecules  to the 
ErbB family of RTKs (EMBO J. 2000 Jul 3;19(13):3159-67). 
 
 
The Ras/MAPK pathway. All RTKs are known to stimulate the exchange of GTP 
for GDP on the monomeric G protein Ras, thus activating it. Biochemical studies in the 
cell lines and genetic studies in Drosophila have established that Ras is activated by the 
guanine nucleotide exchange factor, Sos. The adaptor protein Grb2 forms a complex with 
Sos, then Grb2/Sos complex is recruited to an activated RTK by Grb2 SH2 domain, thus 
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translocating Sos to the plasma membrane where it is close to Ras and can catalyze 
exchange of GTP for GDP (46). Alternatively membrane recruitment of Sos can be also 
accomplished by binding of Grb2/Sos to Shc, another adaptor protein that forms a 
complex with many receptors through its PTB domain (45). Once activated, Ras interacts 
with several proteins, namely Raf. Activated Raf excites MAP-kinase-kinase (MAPKK, 
MEK) by phosphorylating a Ser residue in its activation loop. MAPKK then 
phosphorylates MAPK (ERK1/2) on T and Y residues at the activation-loop leading to its 
activation. Activated MAPK phosphorylates a variety of cytoplasmic substrates 
(MAPKAP) and, when translocated into the nucleus, it also phosphorylates transcription 
factors (54). MAP kinase family members have been found to regulate diverse biological 
functions by phophorylation of specific target molecules (such as transcription factors, 
other kinases, etc.) found in cell membrane, cytoplasm and nucleus, and thereby 
participate in the regulation of a variety of cellular processes including cell proliferation, 
differentiation, apoptosis and imunoresponses (55, 56). 
The PI3K/Akt pathway. The class IA phospholipid kinase PI-3 kinase is activated 
by most RTKs. Like other SH2 domain–containing proteins, PI-3 kinase forms a complex 
with PY sites on activated receptors or with tyrosine phosphorylated adaptor proteins 
such as Shc. Activated PI-3 kinase phosphorylates PtdIns(4)P and PtdIns(4,5)P2 to 
generate the second messengers PtdIns(3,4)P2 and PtdIns(3,4,5)P3. The primary in vivo 
substrate is PtdIns(4,5)P2 (PIP2), which is converted to PtdIns(3,4,5)P3 (PIP3). The class 
IA PI3Ks consist of 2 subunits: regulatory – p85 and catalytic p100. p85 is an adaptor-
like protein that has two SH2 domains and an inter-SH2 domain that binds constitutively 
to the p110 catalytic subunit.  
The primary function of PI3K activation is the generation of PIP3, which functions as a 
second messenger to activate downstream tyrosine kinases Btk and Itk, the Ser/Thr 
kinases PDK1 and Akt (PKB) (57). 
Signaling by the Akt kinase is described below. 
The PLCgamma pathway. PLCgamma is immediately recruited by an activated 
RTK via the binding of its SH2 domains to PY sites of the receptor. When activated 
PLCgamma hydrolyzes its substrate PtdIns(4,5)P2 and forms two second messengers, 
diacylglycerol and Ins(1,4,5)P3. Ins(1,4,5)P3 stimulates the release of Ca2+ from 
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intracellular stores. Ca2+ then binds to calmodulin, which in turn activates a family of 
calmodulin-dependent protein kinases (CamKs). Furthermore, both diacylglycerol and 
Ca2+ activate members of the protein kinase C (PKC) family. The second messengers 
generated by PtdIns (4,5)P2 hydrolysis stimulate a variety of intracellular such as 
proliferation, angiogenesis, cell motylity (58). 
The Src protein tyrosine kinase family. Eight family members have been 
identified in mammals (59). At the N-terminal part they contain SH-2, and at the C-
terminal part catalytic domain, followed by regulatory tyrosine phophorylation site (Y527 
in c-src). When Y527 is phosphorylated, SH-2 domain of c-src itself binds to it, therefore 
folding kinase in inactive conformation (60).  This conformation could be released by 
Y527 dephosphorylation or by binding of c-src SH-2 domain to phosphorylated tyrosines 
on active RTKs (61). SH-2 domain binds to phosphotyrosine sites on RTKs with higher 
affinity than to Y527 and thus allows substrates to access the catalytic domain. The 
activation of Src family kinases appears to be essential for mitogenic signal induced by 
many RTKs, such as PDGFR, NGFR and FGFR. However, the downstream substrates, 
involved in Src signaling, remain elusive. There is evidence, that src activates Ras. It is 
also known that p85 subunit of PI3K can interact with Src, Lyn, and Lck inducing PI3K 
activity (62, 63). Other substrates know to date include estrogen receptor alpha, p130Cas, 
ras-GAP, catenin p120, RACK1, etc. (64-68). 
The JAK/STAT pathway. The binding of cytokines to their receptors leads to 
activation of JAK tyrosine kinases and following tyrosine phosphorylation of STATs. 
The SH2 domain of STAT binds to PY sites on other STAT implementing formation of 
STAT homodimers or heterodimers. The dimeric STATs move to the nucleus and 
function as a transcription factor (69). There is good indication that JAK/STAT signaling 
plays a role in RTK signal transduction. PDGF, EGF, ErbB4 or IGF stimulation leads to 
rapid tyrosine phosphorylation and migration of STATs, namely STAT1, STAT3 and 
STAT5, to the nucleus. (52, 70-72) There were several different mechanisms of STAT 
activation by RTKs described, such as direct phosphorylation or even binding of STATs 
to RTKs (73-75), activation through Src tyrosine kinase (76-78) and “classical” activation 
through JAK family tyrosine kinases (53, 78). 
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1.2.3. ErbB family of RTKs. The type I receptor tyrosine kinases or the ErbB family 
consists of four members who are named for their homology to the v-erbB oncogene: 
ErbB1 (EGFR, HER1), ErbB2 (HER2/Neu), ErbB3 (HER3) and ErbB4 (HER-4) (Fig. 4). 
They have molecular weight of 170-185 kDa and share two structural aspects by which 
they can be distinguished form the other receptor tyrosine kinases: two cysteine rich 
clusters in the extracellular region and an uninterrupted tyrosine kinase domain in the 
cytoplasmic part (79, 80). 
 The EGFR was the first member of the ErbB family and the first of RTKs to be 
cloned and sequenced. It was also the first receptor for which ligand-dependent activation 
was demonstrated (81). The EGFR gene is located on chromosome 7p13-q22 and codes 
for a protein of 1210 amino acids which weighs, when glycosylated, 170 kDa. Ligands 
which bind to the EGFR represent a family of growth factors, called the EGF family. 
This family consists of such members as EGF, TGFα, HB-EGF, amphiregulin 
betacellulin and epiregulin (82-84). Betacellulin, HB-EGF and epiregulin also bind to 
ErbB4 (85-87). The EGFR is the only family member, which is internalized in coated pits 
upon ligand binding, receptor dimerisation and activation. Internalization is followed by 
lyzosomal degradation (88), and partial inactivation through phosphorylation of serine 
and threonine residues within the intracellular domain (89, 90). The EGFR is expressed 
in a variety of normal tissues, including normal breast tissue. Its importance has been 
emphasized by the lethal knock-out mice. A large number of deletion variants of EGFR 
mRNA have been observed in various types of cancer, including breast cancer (91) and 
ovarian cancer (92). These deletions are the result of genomic rearrangements, resulting 
in alternative splicing of the mRNA. They are found both in part of mRNA which 
encodes the extracellular as well as intracellular regions of the EGFR (93) giving rise to 
truncated and often constitutively active receptors (94, 95). 
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Figure 4.  ErbB family members (Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13). 
 
The ErbB2 gene is located on chromosome 17q21 and encodes a protein of 1255 amino 
acids which weighs, when glycosylated, 185 kDa. The human ErbB2 was cloned by 
homology screening with v-ErbB (96) and has the highest homology to the EGFR among 
ErbB family members. It is mostly related to EGFR in its kinase domain (82%) and 
mostly distinct in the C-terminus, which contains most of the autophosphorylation sites. 
ErbB2 is the only orphan receptor of the ErbB family, since no ligand binding it has been 
found up to date. Activation of ErbB2 is therefore highly dependent on the expression of 
other family members, to which it is recruited as a preferred heterodimeric partner (97). 
Alternatively, overexpression and/or mutation of ErbB2 are thought to lead to 
spontaneous dimerisation and the stabilization of the receptor dimmers in a ligand-
independent manner (98-100). Like the EGFR, partial inactivation of the ErbB2 tyrosine 
kinase is mediated by PKC through phosphorylation of serine and threonine residues 
within the intracellular part of the receptor (101). ErbB2 is amplified and/or 
overexpressed in a number of human cancers including gastric, esophageal, salivary, 
colon, bladder and lung cancers (102, 103). ErbB2 overexpression correlates with tumor 
progression and aggressiveness, poor prognosis and an elevated metastatic potential. 
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 ErbB3 and ErbB4 were both found by homology screening. The genes of ErbB3 
and ErbB4 are located on chromosomes 12q13 and 2q33 respectively and code for 
proteins of 1342 and 1308, both of which weigh, when glycosylated, 180 kDa (104, 105). 
The ligands for ErbB3 and ErbB4 , are the various isoforms of the neuregulins (NRG). 
The rate of catalysis of the ErbB3 tyrosine kinase is only 1% of that of the other receptors 
in the family (106). There are four amino acid changes in the kinase domain of ErbB3. 
These four amino acids differ from the sequences of all known protein kinases. The 
change of Asn to Asp is particularly important, since it is responsible for the loss of 
ErbB3 kinase activity. The same amino acid substitution in other tyrosine kinases 
resulted in the loss of function as well (107). Interesting feature of ErbB3 is the presence 
of seven YXXM repeats in the carboxy terminus. These authophosphorylation sites serve 
as docking sites for PI3K. Such motifs are missing in the other family members and 
confer a specific signaling ability on ErbB3 (108). The expression of ErbB3 is in general 
different form that of EGFR and ErbB2, since it is frequently expressed in differentiated 
cells. It is particularly important in the peripheral nervous system and in neuromuscular 
synapse formation (109-111). It has been found both overexpressed and underexpressed 
in DCIS (112) and in breast cancers (106). Prognostic value of ErbB3 is controversial. 
ErbB4 is a unique member of ErbB family: it exists in two isoforms. Sequencing of 
full-length human ErbB4 from either a human MDA-MB-453 breast cancer cell line 
(104) or from human fetal brain tissue (113) revealed the presence of two isoforms, JM-a 
and JM-b, that differ by insertion of either 23 or 13 alternative amino acids in the 
juxtamembrane region. The two isoforms differ in their expression pattern: both are 
expressed in neural tissues, whereas kidney expresses only JM-a and heart only JM-b 
(114). The difference in the juxtamembrane region did not alter the extent of activation 
by heregulins. Nevertheless, a functional difference was observed upon phorbol ester 
treatment. Treatment of JM-a transfected cells, but not JM-b  transfected cells resulted in 
a loss of HRGβ1 binding and reduction in total cell-associated ErbB2 protein levels. JM-
a may thus represent a cleavable receptor form. ErbB4 was found to be downregulated by 
phorbol esters by activating a selective proteolytic mechanism. Proteolytic cleavage 
produces an 80 kDa cytoplasmic domain fragment and a 120 kDa ectodomain fragment. 
Cytoplasmic fragment of ErbB4 is dephosphorylated when cleaved, therefore the 80 kDa 
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fragment is not an active tyrosine kinase. The function  of the proteolytic cleavage id not 
known, but is thought to direct the cytoplasmic domain to proteosome (115). ErbB4 is 
expressed in several adult tissues including heart, kidney, brain and skeletal muscle 
(104). ErbB4 knock-out mice die at embryonic day 10-11 and have severe cardiac and 
neural defects (116). Overexpression of ErbB4 has been observed in 10-20% 
adenocarcinomas of the breast, colon, ovary, prostate and endometrium, whereas 
underexpression were found in 40-80% of the malignancies, reaching 100% in squamous 
cell carcinomas of the head and neck (117).  
1.2.4. Crosstalk between ErbB family and estrogen receptor signaling. Numerous 
in vitro studies demonstrate that hormone-responsive breast cancer cells with upregulated 
ErbB2 display resistance to tamoxifen. On the other hand, reports differ on the effect of 
ErbB2 on estrogen dependence. It has been reported that ErbB2-overexpressing MCF-7 
cells remained estrogen dependent but became tamoxifen resistant (251). Others report, 
that ErbB2 overexpression reduces dependence on estrogen (252, 253). In vivo work in 
general supports the idea that breast cancer cells containing both ER and ErbB2 are 
sensitive to estrogen withdrawal, and resistant to tamoxifen, but over time tumor 
xenografts develop an estrogen-independency. Altogether, these data propose a role for 
ErbB2 in the survival and proliferation of ER positive breast cancers under low estrogen 
environment. A role for EGFR in endocrine therapy resistance has also been established 
in both preclinical and clinical studies (254, 255). Multiple experiments have 
demonstrated that inhibition of ErbB1 and/or ErbB2 with either trastuzumab or a 
selective tyrosine kinase inhibitor can reverse tamoxifen resistance (256-259). Identical 
effect can be achieved through inhibition of the downstream signaling molecules Akt 
(260) and MAPK (261). Moreover, in some cell culture models, long-term exposure to 
estrogen withdrawal induces ErbB2 upregulation and produce ErbB2-dependent 
resistance (262). Preliminary data support the idea that such event may take place 
throughout the development of human breast cancer (263). However, the high expression 
of ErbB2 alone is not a major factor in determining drug resistance in breast cancer cells. 
Coexpression of either EGFR or ErbB3 with ErbB2 significantly enhanced drug 
resistance (264). 
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The biochemical details of the cross-talk between the ErbB2 and ER pathways are 
unclear. The effect of ErbB2 may be to optimize as well as enhance DNA binding, 
interaction with coactivators and transcriptional activity of the ER. On the other hand, 
ErbB2 activates the Ras/MAPK and PI3K/Akt pathways, which may be involved in post-
translational modification of ER (265-267). It is also likely that a combination of post-
translational modifications as well as alterations in the assembly of multi-component 
transcription complexes may occur. 
  Since both ER and ErbB2 positive tumors are relatively uncommon, many studies 
have too few cases to make strong conclusions regarding the clinical behavior associated 
with this biomarker profile. However, results from studies in the advanced disease setting 
do suggest that patients whose tumors overexpress ErbB2 have poorer outcomes after the 
endocrine therapy than patients whose tumors express lower levels of ErbB2 (268). 
Moreover, studies in the adjuvant and neoadjuvant settings support a role for ErbB2 and, 
to a lesser extent, ErbB1 in tamoxifen resistance. Several studies of tamoxifen as adjuvant 
therapy suggest that patients with ErbB2 tumors receiving tamoxifen may even have 
worse outcome than patients receiving placebo (269). In contrast, other studies show that 
patients with both ER and ErbB2 positive tumors can have pretty good outcome with 
endocrine therapy, especially when estrogen withdrawal is a component of the treatment 
strategy (270). Moreover, in a neoadjuvant study for postmenopausal women with ER  
positive locally advanced disease, patients with tumors typed as ER, ErbB1, and/or ErbB2 
positive responded well to letrozole but poorly to tamoxifen (271). These data imply that 
estrogen withdrawal might be an important adjuvant strategy for tumors that are ErbB2 
(possibly ErbB1 as well) and ER positive.  
 
1.3. Shc adaptor proteins. 
Shc was identified by low-stringency hybridizations to human cDNA libraries, using 
an SH2-coding sequence as a probe (118). The originally cloned shc transcript (ShcA) 
displayed two in-frame ATGs and was shown to encode two polypeptides: the 
ubiquitously expressed p52ShcA and p46ShcA proteins. These two isoforms share an 
amino-terminal SH2 domain, followed by a CH1 domain, and a carboxy-terminal 
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phosphotyrosine-binding domain (PTB). A third ShcA isoform, p66ShcA, was later 
characterized (119) (Fig 5).  
 
 
Figure 5. The schematic organization of ShcA isoforms. The PTB and SH2 domains of ShcA bind to 
phosphotyrosine containing sequences. Within the CH domain, three tyrosine-phosphorylation sites have 
been identified. The p46Shc lacks the first 46 amino acids within the PTB domain. The p66Shc possesses 
an additional CH2 domain that contains a serine phosphorylation site (Oncogene. 2001 Oct 1;20(44):6322-
30).
 
 
Biochemical and genetic data prove a general role of p52/46ShcA proteins in the 
transduction of signals from tyrosine kinases (TKs) to Ras (120-121). p52/46ShcA 
proteins are effectively tyrosine-phosphorylated by all TKs tested to date. Three major 
ShcA phosphorylation sites have been identified, which are all located within the CH1 
region (Y239–240 and Y317). The role of phosphorylated p52/46ShcA proteins is to link 
together RTKs and the SH2-containing Grb2 adaptor protein (122-124). The PTB and/or 
SH2 domains of ShcA bind to tyrosine-phosphorylated receptors whereas the SH2 of 
Grb2 binds the tyrosine-phosphorylated ShcA. Grb2, in turn, is constitutively bound to 
Sos, a ubiquitously expressed Ras guanine nucleotide exchange factor. Recruitment of 
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the Grb2/Sos complex, by p52/46ShcA, results in the membrane relocalization of Sos and 
subsequent Ras activation. The centrality of p52/p46ShcA in Ras activation is, however, 
challenged by a several of observations. First, the Grb2/Sos complex can be recruited 
directly to activated receptors with ensuing Ras activation. Second, in cells, derived from 
Shc knockout mouse embryos, Ras activation seems to occur normally (125). It has been 
suggested that p52/p46ShcA might serve as ‘amplifiers’ of RTK signaling, in the 
pathway leading to Ras activation at low concentration of growth factors. However, the 
precise role of ShcA in the activation of Ras is still obscure.  
Alternatively, ShcA proteins might serve other and evidently unrelated functions. 
Homozygous mutation of p66ShcA in mice was shown to cause increased resistance to 
oxidative-stress-induced apoptosis and life-span extension (126). p66ShcA is a third 
isoform encoded by the human and mouse shc loci through alternative splicing (119). It 
contains the entire p52/46ShcA sequence and an additional domain, similar to CH1 
domain, named CH2. Regardless of its tyrosine-phosphorylation by active RTKs, 
p66ShcA is not involved and even seems to inhibit Ras activation (127). Instead, it is 
involved in pathways activated by environmental stresses, as shown by its serine-
phosphorylation within the CH2 domain.  
ShcA proteins were shown to be independent prognostic markers for primary breast 
cancer (272). IHC staining intensities demonstrated that increased amounts of PY ShcA 
and decreased protein expression levels of p66ShcA protein correlated with disease 
recurrence. The ratio of PY ShcA to p66ShcA was 2-fold higher in primary tumors of 
patients who subsequently relapsed.  
Growing complication in the functions of Shc is further projected by the recent 
identification of two human Shc homologues —ShcB and ShcC — which share the same 
PTB–CH1–SH2 modular organization (128, 129). Two isoforms of ShcC have been 
identified — p64ShcC and p52ShcC — which are encoded by the same transcript by 
alternative usage of in-frame ATGs. Preliminary evidence suggests also that ShcB and 
ShcC are RTK substrates, which bind activated receptors through their PTB/SH2 
domains. Unlike ubiquitous ShcA, ShcB and ShcC are specifically expressed in the brain.  
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1.4. Akt signaling. 
 
1.4.1. Structure.  Akt, also termed Protein kinase B (PKB) is a serine/threonine kinase, 
which belongs to the ‘AGC’ superfamily of protein kinases. Akt, as other AGC kinases, 
is regulated by upstream second messengers as well as other enzymes. For Akt, this 
activating process involves multiple inputs that strictly control the place, length and 
power of response. In mammals, there are three isoforms of Akt: Akt1, Akt2 and Akt3 
(PKBα, PKBβ, PKBγ;) (Fig.6). All three isoforms share a high degree of amino acid 
identity and are composed of three functionally different regions: an N-terminal 
pleckstrin homology (PH) domain, a central catalytic (kinase) domain, and a C-terminal 
hydrophobic motif (HM). This general structure is conserved across species including 
Drosophila melanogaster and Caenorhabditis elegans, suggesting that regulation of Akt 
appeared early during the evolution.  
The catalytic domain of Akt is structurally related to other protein kinases of the 
AGC family (130).There are two important regulatory domains, which control the 
activity and specificity of the protein kinase domain. The N-terminal PH domain is 
common to various signaling proteins and provides a lipid binding element to direct Akt 
to PI3K-generated phosphoinositides PI(3,4,5)P3 and PI(3,4)P2. Therefore, growth 
factors that increase PI3K activity provide a plasma membrane recruitment mechanism 
for Akt.  
The crystal structure of the PH domain of PKB bound with the inositol head group of 
PI(3,4,5)P3 has been solved (131). Interestingly, this structure revealed differences in the 
binding between inositol(1,3,4,5)P4 and other PI(3,4,5)P3 binding PH domains, such as 
BTK. The most significant of these differences is that the D5 phosphate of 
inositol(1,3,4,5)P4 does not physically interact with the Akt PH domain, in agreement 
with earlier studies demonstrating that PI(3,4,5)P3 and PI(3,4)P2 bind to Akt with equal 
affinities. This has important implications regarding the upstream phosphatase regulators 
of PI3K-generated lipids, PTEN (132, 133) and SHIP (134). Since PTEN catalyzes the 
dephosphorylation of PI(3,4,5)P3 and PI(3,4)P2 at the D3 position, the actions of this 
phosphatase would reduce the entire pool of lipids capable of binding with Akt.  
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Another important regulatory domain of Akt is a C-terminal HM, present in many 
other AGC kinases (135). The HM provides a docking site for the upstream activating 
kinase, 3-phosphoinositide-dependent kinase-1 (PDK1) (136-138). Interrupting this 
docking interaction severely attenuates phosphorylation of the activation loop (T-loop) of 
AGC kinases. The HM also serves as an allosteric regulator of catalytic activity (130, 
137, 139). The HM provides stability to the catalytic core by association with 
hydrophobic and phosphate binding pockets created by a cleft formed at the junction of 
the αB-helix, αC-helix and β5-sheet in the N-lobe of the kinase domain. Stabilization of 
the N-lobe of the kinase domain by binding of the HM, increases the phosphotransfer rate 
up to 10-fold. Mutations of key phenylalanine residues within the HM compromise 
catalytic activity of Akt (140). 
 
 
 
 
Figure 6. The schematic organization of Akt isoforms. All the Akt isoforms possess the kinase domain 
in the central region of the molecule. The PH (pleckstrin homology) domains act as phosphoinositide-
binding modules. The hydrophobic regulatory (R) motif is located at the carboxyl-terminal adjacent to the 
kinase domain. 
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1.4.2. Phosphorylation. PKB is activated by, and dependent upon, multisite 
phosphorylation. The main site of phosphorylation is within the activation T-loop at 
Thr308 (for Akt1). Phosphorylation of Akt on Thr308, causes a change in conformation 
allowing substrate binding and greatly elevated rate of catalysis. There is very low 
phosphorylation of the activation loop in resting cells and rapid increase in 
phosphorylation upon agonist stimulation. The phosphorylation of Thr308 strictly 
regulates the activation of Akt, and its mutation to alanine impairs the kinase activity 
(141). It has been established that Thr308 is phosphorylated by the PDK1 (142, 143). 
PDK1 phosphorylates Akt in vitro, and overexpression of PDK1 in cells also leads to 
elevated Thr308 phosphorylation in the absence of natural agonists. PDK1 contains a C-
terminal PH domain, and the rate of Akt phosphorylation by PDK1 is significantly 
increased in vitro by the addition of PI(3,4,5)P3 or PI(3,4)P2, which recruits both to a 
plasma membrane (142). In cells in which PDK1 has been disrupted, Akt is unresponsive 
to mitogenic stimulation as a result of a loss of Thr308 phosphorylation (144, 145).  
An additional layer of regulation is provided by HM phosphorylation, namely 
Ser473 phosphorylation (for Akt1). The mechanism of Ser473 phosphorylation is not 
completely understood, and there is evidence suggesting both autophosphorylation (146) 
and phosphorylation by distinct serine kinases, including the integrin-linked kinase (ILK) 
(147, 148). 
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Figure 7. Activation of class IA phosphatidylinositol 3-kinases (PI3Ks) occurs through stimulation of 
receptor tyrosine kinases (RTKs) and the concomitant assembly of receptor–PI3K complexes. These 
complexes localize at the membrane where the p110 subunit of PI3K catalyses the conversion of 
PtdIns(4,5)P2 (PIP2) to PtdIns(3,4,5)P3 (PIP3). PIP3 serves as a second messenger that helps to activate 
AKT. Through phosphorylation, activated AKT mediates the activation and inhibition of several targets, 
resulting in cellular growth, survival and proliferation through various mechanisms (Nat Rev Cancer. 2002 
Jul;2(7):489-501).  
 
Several groups have investigated the possible role of tyrosine phosphorylation in 
Akt regulation (149-151). One report indicated that two tyrosine residues located within 
the catalytic domain of PKB, Y315 and Y326, are phosphorylated following receptor 
activation and are required for activity, since mutation to phenylalanine abolished kinase 
activity (149).A second report identified Y474, as a possible site of phosphorylation in 
response to insulin and pervanadate (151). Mutation of this residue to phenyalanine 
reduced Thr308 phosphorylation and reduced Akt activation by about 50%. A very 
interesting point is that the authors show that S473 and Y474 phosphorylation are 
mutually exclusive: phosphoamino acid analysis and N-terminal sequencing of the tryptic 
peptide containing S473 and Y474 show that neither are phosphorylated together. 
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1.4.3. Functions. The main biological functions of Akt activation can be grouped into 
three categories — survival, proliferation and cell growth.  
Survival. Apoptosis is a normal cellular function that controls cell numbers by 
eliminating 'excessive' cells. Cancer cells have devised several mechanisms to inhibit 
apoptosis and prolong their survival. Akt functions in an anti-apoptotic pathway, since 
dominant-negative alleles of Akt block survival that is mediated by insulin-like growth 
factor 1 (IGF1) (152), and constitutively active Akt rescues PTEN-mediated apoptosis 
(153). The mechanism by which Akt prevents cell death is expected to be multifactorial, 
because Akt directly phosphorylates several components of the apoptotic system. For 
example, BAD is a pro-apoptotic member of the BCL2 family of proteins that promotes 
apoptosis by forming a non-functional hetero-dimer with the survival factor BCL-XL. 
Phosphorylation of BAD by Akt prevents this interaction (154), restoring BCL-XL's anti-
apoptotic function. Likewise, Akt inhibits the catalytic activity of a pro-death protease, 
caspase-9, through phosphorylation (155). Lastly, phosphorylation of members of the 
Forkhead family of transcription factors by Akt prevents its nuclear translocation and 
activation of  gene targets (156), which include several pro-apoptotic proteins. AKT can 
also influence cell survival by means of indirect effects on two central regulators of cell 
death — nuclear factor of κB (NF-κB) (157, 158) and p53 ( 159, 160). 
Proliferation. The cell cycle is regulated by the coordinated action of cyclin–
cyclin-dependent kinase (CDK) complexes and CDK inhibitors (CKIs). Cyclin D1 levels, 
which are important in the G1/S phase transition, are regulated at the transcriptional, 
post-transcriptional and post-translational level by distinct mechanisms. Akt has an 
important role in preventing cyclin D1 degradation by regulating the activity of the cyclin 
D1 kinase glycogen synthase kinase-3β (GSK3β). After phosphorylation by GSK3β, 
cyclin D1 is targeted for degradation by the proteosome. Akt directly phosphorylates 
GSK3β and blocks its kinase activity, thereby allowing cyclin D1 to accumulate (161). 
Akt can also negatively influence the expression of cylin kinase inhibitors, such as p27 
(KIP1) and p21 (CIP1 or WAF1) (162). Akt can also modulate p21 and p27 activity by 
affecting its phosphorylation either directly or through intermediate kinases. The 
functional importance of connections between Akt and the cell-cycle are supported by 
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experiments showing that the blockade of PI3K or Akt activity leads to cell-cycle arrest 
(163-164). 
Cell growth. In addition to its role in proliferation, there is increasing evidence 
that Akt also affects cell growth. A central regulator of cell growth is mTOR (the 
mammalian target of rapamycin), a serine/threonine kinase that serves as a molecular 
sensor that regulates protein synthesis on the basis of the availability of nutrients. mTOR 
regulates biogenesis by activating p70 S6 kinase, which enhances the translation of 
mRNAs that have 5' polypyrimidine tracts, and by inhibiting — a translational repressor 
of mRNAs that bears a 5' CAP structure. mTOR is a direct target of Akt (165), however, 
it is still unclear how or whether phosphorylation of mTOR by Akt is a mechanism for 
activation. Pharmacological studies with the mTOR inhibitor rapamycin indicate that the 
Akt pathway regulates cell growth through mTOR. Yet, the PI3K–AKT pathway is 
unlikely to be the only stimulus that leads to mTOR activation in cancer cells. 
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2. EXPERIMENTAL PROCEDURES 
 
2.1. Materials.  
Separating Gels, in 0.375 M Tris, pH 8.8 
 7% 10% 12% 15% 
distilled H2O 5.15 ml 4.15 ml 3.45 ml 2.45 m 
1.5 M Tris-
HCl, pH 8.8 
2.5 ml 2.5 ml 2.5 ml 2.5 ml 
Acrylamide/Bis-
acrylamide 
(30%/0.8% w/v) 
2.3 ml 3.3 ml 4.0 ml 5.0 ml   
25% (w/v) 
ammonium 
persulfate 
0.05ml 0.05ml 0.05ml 0.05ml 
TEMED 0.005 ml 0.005 ml 0.005 ml 0.005 ml 
Total: 10ml 10ml 10ml 10ml 
 
 
 
 
 
 
 
Stacking Gels, 4.0% gel, 0.125 M Tris, pH 6.8 
distilled H2O 3.1 ml 
1.5 M Tris-HCl, pH 8.8 1.25 ml 
Acrylamide/Bis-acrylamide (30%/0.8% w/v) 0.67 ml 
25% (w/v) ammonium persulfate 0.025ml 
TEMED 0.005 ml 
Total: 5.05 ml 
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Resolving gel buffer: 100 ml  
0.4 g SDS (add last)  
18.2 g Trizma base (= 1.5M)  
Adjust pH to 8.8 with concentrated HCl  
 
Stacking gel buffer: 100 ml  
0.4 g SDS (add last)  
6.05 g Trizma base (= 0.5 M)  
Adjust pH to 6.8  
 
10x Running buffer: 1 L  
30.3 g Trizma base (= 0.25 M)  
144 g Glycine (= 1.92 M)  
10 g SDS (= 1%)--add last  
Do not adjust the pH!!  
 
Blotto: 0.5 L  
2.5% Nonfat dry milk powder  
Make up in PBS.  
Then add 0.05% Tween 20.  
Keep at 4°C to prevent bacterial contamination.  
 
10x Transfer buffer: 1 L  
30.3 g Trizma base (= 0.25 M)  
144 g Glycine (= 1.92 M)  
pH should be 8.3; do not adjust  
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To make 2 L of 1x Transfer buffer:  
400 ml Methanol  
200 ml 10x Transfer buffer  
1400 ml water  
 
Stripping buffer: 0.5 L  
62.5 mM Tris-HCl pH 6.8  
2% (w/v) SDS  
100 mM b-mercaptoethanol  
 
 
 
2.2. Cell culture. SKBr3 and MCF-7 breast cancer cell lines obtained from American 
Type Culture Collection (Manassas, VA), were cultured in Improved Minimal Essential 
medium with zinc option (IMEM-ZO) supplemented with 5% fetal bovine serum and L-
glutamine at 37°C in a 5% CO2 incubator. 
For use as an immunoassay standard, subconfluent (70-80%) SKBr3 or MCF-7 cells were 
serum-starved for 48 h in serum free medium, treated with Na3VO4 or NaF for 1 hr., then 
with 10% FBS for 10 min. Cells were lysed in EB lysis buffer as described below. 
For lysis, cells were washed 3X with ice-cold PBS. 0.5-1ml of EB buffer (0.5 M NaCl, 
10 mM EDTA, pH 8, 1% Triton X100, 20 mM Tris-Cl, pH 7.0, 20mM NaF, 20mM 
glycerophosphate, 2 mM sodium pervanadate, 1 mM PMSF, phosphatase inhibitor 
cocktail (Roche)) was added to the cells and cells lysed for 5 min, on ice. Cells were then 
scraped using “rubber policeman” and lysate transferred to eppendorf tube and spun at 20 
000g for 5 min. at 4ºC. Supernatant was transferred to new eppendorf tube and stored at -
80ºC.  
2.3. Tumor extract preparation for immunoassays. Tissue homogenates were prepared 
in accordance with standard procedures for tumor marker EIA measurement. The frozen 
tissues were pulverized in liquid nitrogen using a Micro-Dismembrator U (B. Braun 
Melsungen AG, Melsungen, Germany). The powder was homogenized with a tissue 
homogenizer (Ultra-Turrax; Janke & Kunkel, IKA-Werke, Staufen, Germany) for 20 
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seconds in three volumes of ice-cold extraction buffer containing Tris 10 mmol/L, EDTA 
1.5 mmol/L, 10% glycerol, disodiummolybdate 5 mmol/L, and monothioglycerol 1 
mmol/L. The homogenate was centrifuged for 3 minutes at 4°C, and the supernatant was 
recentrifuged in an ultracentrifuge (Beckman Instruments, Fullerton, CA) at 100,000g for 
40 minutes at 4°C. 
2.4. Measurement of ER and PgR levels. The cytosols, resulting from the above 
described procedure were used for measurement of the hormone receptors (ER, PgR). ER 
and PgR concentrations were measured from tumor cytosolic extracts by commercial 
quantitative ER and PgR EIA kits (Abbott Laboratories, Abbott Park, IL) using a 
Quantum II photometer.  
2.5. Immunoassay of total ErbB2 receptor levels. ErbB2 receptor levels were 
determined on the particulate membrane fractions of tumor extracts using a commercial 
monoclonal antibody EIA kit. The cryopreserved pellet fraction obtained from the high-
speed tumor extract (above) was washed once with cold magnesium chloride solution 
(0.5 mol/l) and three times with cold Tris hydrochloride buffer (10 mmol/L, pH 7.4) 
containing EDTA 1 mmol/l. Washed pellets were suspended on ice in 5 volumes of a 
buffer containing HEPES 20 mmol/l (pH 7.4), 10% glycerol, leupeptin 10 mg/l, and 
aprotinin 2 mg/l. The pellet suspension was then further diluted with HEPES-glycerol-
aprotinin-leupeptin buffer containing 0.1% of Triton X-100. Protein concentrations of 
these diluted extracts were determined using the Pierce BCA (bicinchoninic acid) Protein 
Assay (Pierce, Rockford, IL). Quantitative assessment of ErbB2 protein levels was 
carried out with immunoassay kit (Oncogene Science kit; Oncogene Science, Cambridge, 
MA), according to the manufacturer’s instructions. Color intensity was measured on a 
COBAS EIA spectrophotometer (Hoffmann-La Roche Ltd, Basel, Switzerland). Internal 
quality control was performed during each run using the controls provided with each kit. 
2.6. Immunoassay of P-Y1248 ErbB2 levels. Black ninety-six–well microtiter plates 
(Nunc Black MaxiSorp Surface; Nalgen Nunc International, Rochester, NY) were coated 
with antihuman activated neu/c-ErbB2 antibody no. 06-229 (lot no.15916; Upstate 
Biotechnology, Lake Placid, NY) at a concentration of 4 mg/mL of coating buffer (PBS 
with 0.6 mM EDTA) in a volume of 100 µl/well and kept at 4°C overnight. This rabbit 
polyclonal antibody was raised against a phosphorylated polypeptide containing the C-
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terminal autophosphorylation site of ErbB2, virtually identical to the phosphorylated 
epitope used to produce the monoclonal antibody clone PN2A that recognizes only 
PY1248 ErbB2 used in several previous studies (25-29). For determination of 
phosphorylated ErbB2 tumor extracts were prepared as described above in the presence 
of Na3VO4. Before sample applications, the coated microtiters were washed five times 
with 200 µl/well of washing buffer (25mM HEPES, pH 7.4, 300 mM NaCl, 0.05% 
Tween-20) and then blocked for 2 hours at room temperature with 250 µl of blocking 
buffer (25mM HEPES, pH 7.4, 300 mM NaCl, 0.05% Tween-20, 3% TopBlock, Juro 
AG, Switzerland). The blocked wells were washed five times with 300 µl of blocking 
buffer and then 100 µl of the diluted tumor membrane extracts or reference material was 
added to the wells and incubated overnight at 4°C. As a reference for each assay, a s cell 
extract of SKBr3 cells, stimulated as described above, was used. For use in ELISAs, the 
SKBr3 cell membrane extract was sequentially diluted with sample dilution buffer at 
ratios of 1X, 0.75X, 0.5X, 0.25X, 0.125X, and 0.025X, and then 100 µl aliquots were 
incubated on each microtiter plate together with the tumor tissue extracts and blanks 
(containing only dilution buffer). After incubation of the samples and references, the 
wells were washed five times with 300 µl washing buffer at room temperature to 
eliminate unbound particles. Biotinylated detection antibody (detecting antibody from 
HER-2/neu Microtiter ELISA kit, OncogeneScience) was added to the wells and 
incubated for 2 hrs at room temperature. Complex was detected with horseradish 
peroxidase (HRP)-conjugated streptavidin, diluted in conjugate diluent for 1 hr at room 
temperature. HRP activity was detected with SuperSignal WestPico substrate (Pierce, 
Rockford, IL) in glow luminometer. The response data of the series of diluted reference 
material were fitted and the curve was used for quantification of the tumor extracts. The 
value of the undiluted SKBr3 extract was denominated 100 U/ml. 
2.7. Immunoassays of pan-Y, S and T phosphorylation of ErbB2. Black ninety-six–
well microtiter plates (Nunc Black MaxiSorp Surface; Nalgen Nunc International, 
Rochester, NY) were coated with monoclonal Anti-c-ErbB2 no. E2777 (clone HER2-96, 
Sigma,) at a concentration of 4 mg/mL of coating buffer  in a volume of 100 µl/well and 
kept at 4°C overnight. For determination of phosphorylated ErbB2 tumor extracts were 
prepared as described above in the presence of Na3VO4. Before sample applications, the 
 42
coated microtiters were washed five times with 200 µl/well of washing buffer and then 
blocked for 2 hours at room temperature with 250 µl of blocking buffer. The blocked 
wells were washed five times with 300 µl of blocking buffer and then 100 µl of the 
diluted tumor membrane extracts or reference material was added to the wells and 
incubated overnight at 4°C. As a reference for each assay, a s cell extract of SKBr3 cells, 
stimulated as described above, was used. For use in ELISAs, the SKBr3 cell membrane 
extract was sequentially diluted with sample dilution buffer at ratios of 1X, 0.75X, 0.5X, 
0.25X, 0.125X, and 0.025X, and then 100 µl aliquots were incubated on each microtiter 
plate together with the tumor tissue extracts and blanks (containing only dilution buffer). 
After incubation of the samples and references, the wells were washed five times with 
300 µl washing buffer at room temperature to eliminate unbound particles. Biotinylated 
PhosphoSerine Antibody Q5, Cat. No. 37430 or PhosphoThreonine Antibody Q7, 
Cat. No. 37420 (Qiagen, Chatsworth, CA) or alkaline phosphatase (AP) conjugated 
PhosphoTyrosine antibody PY20, Cat. No. 03-7722 (Zymed Laboratories Inc., South San 
Francisco, CA) was added to the wells and incubated for 2 hrs at room temperature. 
Complex was detected with AP-conjugated streptavidin, diluted in conjugate diluent for 1 
hr at room temperature. AP activity was detected with CDP Star substrate (Tropix, 
Bedford, MA) in glow luminometer. The response data of the series of diluted reference 
material were fitted and the curve was used for quantification of the tumor extracts. The 
value of the undiluted SKBr3 extract was denominated 1 U/ml. 
2.8. Immunoassay of P-Akt level. Black ninety-six–well microtiter plates (Nunc Black 
MaxiSorp Surface; Nalgen Nunc International, Rochester, NY) were coated with anti-
Akt/PKB, PH domain antibody, clone SKB1, Cat. No. 05-591 (Upstate Biotechnology, 
Lake Placid, NY) at a concentration of 3 mg/mL of coating buffer in a volume of 100 
µl/well and kept at 4°C overnight. For determination of phosphorylated Akt tumor 
extracts were prepared as described above in the presence of Na3VO4. Before sample 
applications, the coated microtiters were washed five times with 200 µl/well of washing 
buffer and then blocked for 2 hours at room temperature with 250 µl of blocking buffer. 
The blocked wells were washed five times with 300 ml of blocking buffer and then 100 
ml of the diluted tumor membrane extracts or reference material was added to the wells 
and incubated overnight at 4°C. As a reference for each assay, a cell extract of MCF-7 
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cells, stimulated as described above, was used. For use in ELISAs, the MCF-7 cell 
membrane extract was sequentially diluted with sample dilution buffer at ratios of 1X, 
0.75X, 0.5X, 0.25X, 0.125X, and 0.025X, and then 100 µl aliquots were incubated on 
each microtiter plate together with the tumor tissue extracts and blanks (containing only 
dilution buffer). After incubation of the samples and references, the wells were washed 
five times with 300 µl washing buffer at room temperature to eliminate unbound 
particles. Biotinylated detection antibody (Phospho-Akt (Ser473), clone 4E2, Cell 
Signaling Technologies, Beverly, MA) was added to the wells and incubated for 2 hrs at 
room temperature. Complex was detected with horseradish peroxidase (HRP)-conjugated 
streptavidin, diluted in conjugate diluent for 1 hr at room temperature. HRP activity was 
detected with SuperSignal WestPico substrate (Pierce) in glow luminometer. The 
response data of the series of diluted reference material were fitted and the curve was 
used for quantification of the tumor extracts. The value of the undiluted MCF-7 extract 
was denominated 1 U/ml. 
2.9. Immunoassay of pan-Y and S phosphorylation of ShcA. Black ninety-six–well 
microtiter plates (Nunc Black MaxiSorp Surface; Nalgen Nunc International, Rochester, 
NY) were coated with anti-Shc antibody, Cat. No. 06-203 (Upstate Biotechnology, Lake 
Placid, NY) at a concentration of 3 mg/ml of coating buffer in a volume of 100 µl/well 
and kept at 4°C overnight. For determination of phosphorylated ShcA tumor extracts 
were prepared as described above in the presence of Na3VO4. Before sample applications, 
the coated microtiters were washed five times with 200 µl/well of washing and then 
blocked for 2 hours at room temperature with 250 µl of blocking buffer. The blocked 
wells were washed five times with 300 µl of blocking buffer and then 50 µl of the diluted 
tumor membrane extracts or reference material was added to the wells and incubated 
overnight at 4°C.  As a reference for each assay, a s cell extract of SKBr3 cells, 
stimulated as described above, was used. For use in ELISAs, the SKBr3 cell membrane 
extract was sequentially diluted with sample dilution buffer at ratios of 1X, 0.75X, 0.5X, 
0.25X, 0.125X, and 0.025X, and then 100 µl aliquots were incubated on each microtiter 
plate together with the tumor tissue extracts and blanks (containing only dilution buffer). 
After incubation of the samples and references, the wells were washed five times with 
300 µl washing buffer at room temperature to eliminate unbound particles. Biotinylated 
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PhosphoSerine Antibody Q5, Cat. No. 37430 or PhosphoThreonine Antibody Q7, 
Cat. No. 37420 (Qiagen, Chatsworth, CA) or alkaline phosphatase (AP) conjugated 
PhosphoTyrosine antibody PY20, Cat. No. 03-7722 (Zymed Laboratories Inc., South San 
Francisco, CA) was added to the wells and incubated for 2 hrs at room temperature. 
Complex was detected with AP-conjugated streptavidin, diluted in conjugate diluent for 1 
hr at room temperature. AP activity was detected with CDP Star substrate (Tropix, 
Bedford, MA) in glow luminometer. The response data of the series of diluted reference 
material were fitted and the curve was used for quantification of the tumor extracts. The 
value of the undiluted SKBr3 extract was denominated 1 U/ml. 
2.10. RNA extraction, quantification and quality check (performed by OncoScore, 
AG staff).  Total RNA was extracted from powdered tumor tissue aliquots using the 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s recommendations. Purified 
RNAs were stored at -70˚C. RNA was quantified and checked for quality by the 
Bioanalyzer 2100 and the RNA 6000 Nano LabChip-Kit (Agilent Technologies) 
following the manufacturer’s recommendations. 
2.11. cDNA Synthesis (performed by OncoScore, AG staff). 1µg of good quality total 
RNA was reverse transcribed in a final volume of 20µl. Final concentrations were 10mM 
DDT, 1µg of hexamer primers, 2 U of MMLV Reverse Transcriptase (Invitrogen), 40 U 
of RNasin (Promega), 0.5mM of each dNTP (Promega), 1x reaction buffer. RNA, 
hexamer primers and dNTPs were incubated for 5’ at 65˚C, cooled for 5’ at 4˚C and 
subsequently treated for 10’ at 25˚C before the rest of the reaction mix was added. 
Reverse transcription was carried out at 37˚C for 50’ followed by 5’ at 42˚C. As soon the 
reaction was completed 180µl of H2O were added and cDNAs were stored at -20˚C until 
use.  
2.12. Primer design (performed by OncoScore, AG staff). Primers were designed 
using the Primer Express™ v2.0 software (Applied Biosystems, Forster City, CA). All 
primer sequences were blasted against the dbEST and nr databases to confirm their 
specificity and from GeneScan Europe (Freiburg, Germany). All primer sets were chosen 
to work at the same conditions (AT=60˚C) and to be cDNA specific. All primer sets were 
tested in Qrt-PCR reactions on universal human reference RNA (Stratagene, La Jolla, 
CA).  
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2.13. Quantitative real-time RT-PCR (performed by OncoScore, AG staff). PCR was 
performed in 40 cycles on a ABI Prism 7000 using the 2x SYBR Green I Master Mix 
(Applied Biosystems, Forster City, CA) in a final volume of 25µl. After PCR, all 
amplicons were submitted to a temperature ramping and analyzed for their melting points 
and sequenced. Relative quantification (µCt) was obtained by normalization with 
ribosomal 18S. Qrt-PCR results were expressed in arbitrary Units per µg reverse 
transcribed RNA (U/µg rt-RNA). All three markers were measured in parallel. Inter-assay 
variation was monitored on Human Universal Standard RNA (Stratagene) using GSTP 
(glutathione S-transferase-P1) as reference gene. The assays were highly reproducible 
with a coefficient of variation less than 0.15 among the different run. 
2.14. EGF binding assay for EGFR quantification. Binding assays were carried out in 
96-well plates in a total volume of 250 µl. All plasticware was preblocked with a 1% 
BSA solution before use. Final reaction concentrations were 20 mM HEPES, pH 7.5, and 
0.1% BSA containing 20 µg of membrane preparation in the presence or absence of 
crocidolite asbestos or riebeckite. The final concentration of asbestos in the binding 
reactions was calculated to be approximately equivalent to 5 µg/cm2 of cell membrane. 
An excess of unlabeled EGF (final concentration 4 µM) was added to the tubes in which 
nonspecific binding was to be measured. Stock solutions were divided into aliquots into 
microwells containing increasing amounts 125I-EGF to initiate the binding reactions. The 
binding assay was conducted at room temperature for 1 h. The reaction mixtures were 
diluted in 1 ml of 20 mM HEPES (pH 7.5) and 0.1% BSA. The dilute reaction mixtures 
were filtered to separate receptor-bound 125I-EGF from free ligand by use of a vacuum 
filtration manifold. Reaction mixtures were filtered through glass microfiber filters 
(Whatman, Maidstone, UK; Schleicher & Schuell, Keene, NH) that had been wetted with 
HEPES-BSA. After filtration, each filter was washed several times with HEPES-BSA. 
Filters were then counted in a gamma spectrometer. Samples were analyzed in duplicate. 
Total binding corresponded to conditions in the absence of unlabeled EGF, across which 
increasing concentrations of 125I-EGF were titrated. Nonspecific binding corresponded to 
conditions in which there was an excess of unlabeled EGF. Specific binding was 
calculated by subtracting nonspecific binding from total binding. 
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2.14. Sample preparation for SDS-PAGE.  The supernatant of a cell lysate obtained as 
described above was mixed 1/1 with 2x protein sample buffer (125 mM Tris Base, 20% 
(v/v) Glycerol, 2% (w/v) SDS, 0.02% Bromphenol blue, 2% mertcaptoethanol), heat for 
5 min. at 95ºC. Store at -80C.  
2.15. SDS-PAGE. Protein gel buffers were cast as described by Laemmli et al. (276) 
using buffers described in material section. The BioRad Modular Mini-Protean II 
Electrophoresis Gel System was used for protein electrophoresis. 
2.16. Western-Blotting. Western blot analysis. The proteins were resolved on a 10% 
sodium dodecyl sulfate (SDS)-polyacrylamide gel as described above, transferred to 
Immobilon (Millipore) membrane using buffers described below, incubated for 1 h at RT 
in BLOTTO, and subsequently probed with the primary antibody for 3 to 4 h at room 
temperature or overnight at 4°C. The primary antibody diluted 200-2000x in BLOTTO 
was used to detect the relevant protein. Following incubation with the primary antibody, 
the blots were rinsed with PBST (0.05% Tween-20 in PBS) and probe for 1 h at room 
temperature with a species-specific secondary antibody conjugated to horseradish 
peroxidase (HRP), the blot was washed again with PBST and then with PBS and 
subjected to ECL detection. Membranes were stripped using stripping buffer and 
reprobed with another antibodies, when necessary. 
2.17. ECL detection. HRP- conjugated secondary antibodies we detected using 
SuperSignal West Pico Chemiluminescent Substrate. Two substrate components were 
mixed at a 1:1 ratio to prepare the substrate Working Solution. Blot was incubated for 5 
minutes in Working Solution. Excess reagent was drained and blot was covered with 
clear plastic wrap. Blot was then exposed to X-ray film. 
2.18. Computing. The SofMax program was used for curve-fitting and marker amount 
quantification (U/ml). The Prism and S+ programs were used for statistical analysis and 
drawing of graphs.  
2.19. Statistics. Statistical significance of the association between P-Akt and other 
dichotomous variables (e.g., nodal status), was assessed by Mann-Whitney test. The 
continuous variable function of CLISA-determined P-Akt values was first tested for 
prognostic significance by univariate Cox regression analysis against patient relapse rate. 
A cut-off or prognostic threshold value was searched for by means of classification and 
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regression trees analysis (CART) (273, 274). Survival probabilities were calculated by 
the Kaplan-Meier method and compared by means of logrank analysis (275). Spearman 
rank correlation (rs) was calculated to assess associations between continuous markers 
(e.g. P-ErbB2 and EGFR protein expression levels). 
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3. Immunoassay development 
 
3.1. Introduction. 
A direct way to assess specific activation of kinases or other signaling proteins is by 
analysis of their phosphorylation (80, 166, 167). Analyses of protein phosphorylation 
have previously relied primarily on slide-based immunohistochemistry (IHC) or Western 
blot analyses with enzyme-conjugated phosphospecific antibodies (168, 169). Typically 
these techniques are time-consuming and have low sample throughput. Moreover, in the 
case of Western blot analysis, accurate quantitation can also be very cumbersome, while 
in case of IHC semiquantitative scoring systems are used, which are subject to 
interobserver interpretation error and which prevent statistical analysis of the values as a 
continuous variable function. On the other hand, assays performed on frozen or fresh 
tumor tissue produce more consistent results than those subject to variable types of tissue 
fixation and archival storage of paraffin-embedded sections. It is often the case, that, 
different IHC antibodies different staining patterns and intensities depending on the type 
of tissue fixative and the length of slide storage. 
Enzyme immunoassay (EIA) measurement of phosphorylated protein levels averts the 
potential antigen damage associated with fixation, embedding, and uncontrolled storage 
and yields a highly reproducible continuous value results. However a disadvantage of 
such methods is the requirement for relatively large quantities of fresh or frozen tumor 
tissue.  Furthermore, the two-site (sandwich) EIA assays ensure increased specificity as 
compared to one-antibody assays such as IHC and Western Blotting 
We have developed a rapid, sensitive, and high-throughput kinase phosphorylation assays 
termed a two-site chemoluminescence-linked immunosorbent assay (CLISA) to analyze 
protein phosphorylation in well-characterized primary breast cancer samples. Since 
chemoluminometric detection provides higher sensitivity for the detection of 
antigen/antibody complex as compared to colorimetric assays, we have expected 
detection of phosphoproteins in the present study to be extremely sensitive as well as 
specific and precise. 
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3.2. Results.  
 Seven assays have been developed: PY1248 ErbB2, pan-PY ErbB2, pan-PS ErbB2, pan-
PT ErbB2, PS473-Akt, pan-PY Shc and pan-PY Shc assays. Since all the assays have 
undergone exactly the same validation procedures, below will be presented an example of 
the assay development, the development of a pan-PY Shc assay. 
 
3.2.1. Western Blotting. Western Blotting, as a standard assay, was used in order to 
check the performance of newly purchased antibodies. Proteins from SkBr3, BT474, 
MCF-7 and BT20 cell lysates were separated using 10% SDS PAGE gel and transferred 
to PVDF membrane (Milipore). Western Blot was visualized using SuperSignal 
WestPico ECL detection reagents (Fig. 8). 
 
 
 
MW       MCF-7  BT474  SKBr3  THP-1
←p46
←p52
 
Figure 8. Western blotting with the anti-ShcA antibody was performed in human cell lines ( MCF-7, 
BT474, SKBr3 and THP-1 cells) as described under "Experimental Procedures." ShcA protein was detected 
as ~50-kDa bands (see arrows).  
 
3.2.2. Dose-response curve, LOD and LOQ. Different antibody pairs were tested using 
series of  standard dilutions (undiluted, 5X, 25X, 125X, 625X,  3125X, 15625X, 78125X, 
390625X and 1953125X diluted standard). As shown in Fig. 9 dilution curve could be 
drawn only if the assay was functional. 
 
Limit of detection (LOD) and limit of quantification (LOQ) was calculated from the 
dose-response curve. LOD was calculated as the doses of signals at two-fold standard 
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deviation above blank level, LOQ at ten-fold standard deviation above blank level. LOD 
of PY-ShcA assay was 0.00027 U/ml , LOQ - 0.062 U/ml 
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Figure 9. Dose-response curve. 
 
3.2.3. Specificity. In order to test the specificity of the assay and the extent of nonspecific 
binding, different controls were used, omitting one reagent required for the assay. As 
seen in Fig. 10, assays lacking either analyte or detecting antibody or substrate or 
conjugate or coating antibody, show at least 8 fold lower RLU than the assay containing 
all the components. Species-specific antibody directed against the coating antibody was 
used as a positive control, and shows 12 fold higher RLU than the normal assay. 
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Figure 10. Controls used in the assay in order to role out nonspecific binding. Assays lacking one 
component, show only a background RLU as compared to the complete assay. 
 
 
3.2.4. Phospho-specificity. In order to test whether the assay was specific for the 
pohosphorylated form of ShcA, BT20 and BT474 cell lines were serum starved for 48 hrs 
and either lysed untreated or treated with EGF or Na3VO4 . Lysates were normalized for 
total protein content and measured using newly developed assay. In BT20 and BT47 cell 
lines EGF treatment increased RLU 1.3 fold and 3.3 fold respectively, and Na3VO4  
treatment – 1.7 fold and 10.5 fold respectively (Fig. 11), suggesting that the assay indeed 
detects phosphorylated form of ShcA. 
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Figure 11. The proof of a phospho-specificity of the assay. EGF or Na3VO4 treatment increased RLU 
readings, confirming the phospho-specificity of the assay. 
 
3.2.5. Standard curve. The value of the undiluted SKBr3 extract was denominated 1 
U/ml. 
The response data of the series of diluted reference material (1, 0.75, 0.5, 0.25, 0.125 and 
0.025 U/ml) and blanks (only dilution buffer: 0 U/ml) were fitted and the standard curve 
(Fig. 12) was used for quantification of the tumor extracts.   
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Figure 12. The standard curve: Excel graph (A) and SoftMax graph (B). 
 
3.2.6. The raw data. After the measurement cancer sample values were calculated by 
fitting the standard curve, using SoftMax Pro software.  The resulting raw result (U/ml) 
(Fig. 12) were divided by total sample protein levels (mg/ml) in order to obtain absolute 
PY ShcA content in given tumor sample (U/mg of total protein contents).  
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Figure 13. The mean result of PY ShcA detection in 25 samples after fitting the standard curve. 
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3.2.7. Final result. We applied a novel immunoassay in primary breast tumor tissue 
samples of 157 breast cancer patients. For the entire collective CLISA quantified PY 
ShcA levels ranged from 0 to 32.33 U/mg with a median of 3.997 U/mg (mean 4.59 
U/mg).  The distribution of PY ShcA levels in these samples is shown in Fig. 14. 
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Figure 14. Histogram showing distribution of PY ShcA levels in 157 primary breast cancer samples. 
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4. The role of Y1248 ErbB2 phosphorylation in primary 
breast cancer. 
 
4.1.
 Introduction. 
 
ErbB2 is amplified and overexpressed in 10-30% of breast cancers (170-172). It’s 
amplification and overexpression have been associated with poor prognosis or response 
to anticancer therapies (173). An inverse relationship between estrogen receptor and 
ErbB2 expression has been reported in breast cancer, with overexpression associated with 
decreased sensitivity to endocrine therapy (172; 174-175). Therapy based on a humanized 
monoclonal anti-ErbB2 antibody (trastuzumab/Herzeptin™) has been beneficial in 
metastatic patients (27). Trastuzumab is the first clinically available oncogene-targeted 
therapeutic agent for treatment of solid tumors. First-line trastuzumab in combination 
with chemotherapy resulted in a 25% improvement in overall survival compared with 
chemotherapy alone, but still a maximum of 40% of patients profit. Moreover, different 
groups have postulated a possible resistance to SERM in breast cancer patients whose 
tumors overexpress ErbB2 (174; 176). Therefore, more precise identification of the 
patients that are more likely to respond to such treatment is necessary in order to improve 
survival and quality of life.  
ErbB2 (Her2/Neu) is a member of the epidermal growth factor receptor (EGFR) family 
of receptor tyrosine kinases, which includes EGFR(HER1, ErbB1), ErbB3(HER3) and 
ErbB4(HER4) (177-180). This family of receptors regulates cell proliferation through 
activation of downstream signal transduction cascades. The ErbB2 molecule is composed 
of an extracellular ligand binding domain, a transmembrane region and an intracellular 
region, which contains tyrosine kinase domain and a carboxy tail with five major 
autophosphorylation sites (80). Ligand binding initiates the formation of homo- and 
heterodimeric complexes with other EGFR family members into which ErbB2 is 
recruited as preferential dimerisation partner (84). This promotes autophosphorylation of 
specific tyrosine residues, which provide docking sites for a variety of proteins involved 
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in the activation of downstream intracellular signaling cascades (41). In vitro 
overexpression of ErbB2 can result in receptor autophosphorylation and activation even 
in the absence of the activating ligands (181-184). Activating mutations have been 
described experimentally, but none has been detected in human tumors (185-188). It has 
also been suggested that shedding of the extracellular domain may represent an 
alternative activation mechanism of ErbB2 (189-190). Amplification or overexpression of 
ErbB2 has been demonstrated in many epithelial tumors, such as breast, prostate and non 
small cell lung cancers (191-193). 
However, ErbB2 gene amplification or overexpression may not necessarily reflect the 
functional status of the receptor and it has been hypothesized that ErbB2 could be 
activated to different degrees in tumors expressing the same amounts of the receptor. So 
far, several studies have investigated the phosphorylation of ErbB2 in breast tumors and 
its possible association with poor prognosis or prediction of therapies (171; 194-198). 
The primary aim of the present study was to revalidate our previous results (171) on the 
prognostic role of PY1248 ErbB2in patients overexpressing ErbB2 as well as in patients 
with intermediate levels of ErbB2. A secondary aim was to determine possible 
associations between phosphorylation of ErbB2, and the expression levels of EGFR 
family members as well as estrogen receptor (ER) and progesterone receptor (PgR). 
 
 
4.2. Results.  
 
 
4.2.1. Tumor and Patient Characteristics.  A new collective of 70 well characterized 
primary breast tumors cryopreserved (-80°C) in our tumor bank, were selected according 
to the ErbB2 expression levels previously routinely detected by ELISA at the time of 
surgery. Thirty tumors overexpressed ErbB2, the remaining 30 had intermediate (100-260 
ng/mg) levels. During a median follow-up time of 55 months (range 30 to 89 months) 14 
(20%) patients died because of the disease and 24 (34%) developed a relapse. Fifty (71%) 
cases were ER positive tumors (>20 fmol/mg protein), 38 (54%) PgR positive tumors 
(>20 fmol/mg protein). Thirty three (47%) cases were node-positive tumors and 34 (48%) 
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of the tumors were grade III. Most of the tumors (42) were of medium size (T2), 18 
(26%) T1 and 10 (14%) T3. Median age of patients was 56 (range 28-82)(Tables 1, 2).  
 
Table 1. Clinicopathological Characteristics of the Patients 
Feature Number of patients (%) 
Patients enrolled 70 
Histology type 
  Ductal 
  Lobular   
  Other   
 
48 (69) 
11 (16) 
11 (16) 
Tumor size 
  T1 
  T2 
  T3-4 
 
18 (26) 
42 (60) 
10 (14) 
Lymph-node status 
  Node-negative 
  Node-positive 
 
33 (47) 
37 (53) 
Histopathological grade 
  I + II 
  III 
  Not analyzed 
 
27 (39) 
34 (48) 
9    (13) 
Estrogen receptor (ER) 
  Positive (>20 fmol/mg) 
  Negative (≤ 20 fmol/mg) 
 
50 (71) 
20 (29) 
Progesterone receptor (PgR) 
  Positive (>20 fmol/mg) 
  Negative (≤ 20 fmol/mg) 
38 (54) 
32 (46) 
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Table 2. Features of the Entire Primary Breast Tumor Collective 
Factor Median Mean Range 
Age 56 58 28-82 
ER 72 fmol/mg 139 fmol/mg 2-625 fmol/mg 
PgR 28 fmol/mg 129 fmol/mg 0-1250 fmol/mg 
ErbB2 308 ng/mg 299 ng/mg 121-654 ng/mg 
 
 
4.2.2. Distribution of PY1248 ErbB2 Levels in Breast Cancer Membrane Fractions. 
For the entire collective of 70 tumors (whose clinicopathological features are described in 
Table 1), CLISA quantified ErbB2 levels ranged from 0 to 127.304 U/mg with a median 
of 1.0955 U/mg (mean 7.49 U/mg) (Figure 15). Increased levels of tyrosine 1248 
phosphorylated (PY1248) ErbB2 were found in ErbB2 - overexpressing tumors, median 
2.89 U/mg (mean 12.41 U/mg) as compared to low-ErbB2-expressing tumors, median 
0.39 U/mg (mean 0.93 U/mg). 27% (8 of 30) of low-ErbB2-expressing tumors contain 
PY1248 ErbB2 above clinically the relevant threshold value (see below), and 68% 
(27/40) of ErbB2 - overexpressing tumors.  
 
 
 
 59
0
5
10
15
20
25
30
35
40
45
50
0 10 20 30 40 50 60 70 80 90 100 110 120 Mo
re
U/mg
Fr
eq
u
en
cy
 
Fig 15.  Histogram showing distribution of CLISA-determined PA1248 erbB2 expression levels in 70 
primary breast cancer samples. 
 
 
4.2.3. Prognostic Significance of CLISA-Determined Threshold Value of Tumor 
PY1248 ErbB2 Levels. To determine whether there were any significant biologic 
difference between groups of tumors containing increased levels of  PY1248 ErbB2 
quantified by CLISA, particularly those distributed above or below the median PY1248 
ErbB2 value (1.0955 U/mg), patient outcome was evaluated with respect to different 
tumor ErbB2 phosphorylation levels measured in 70 samples. As shown by the Kaplan-
Meier plots of Fig. 16, patients with high PY1248 ErbB2 tumors not only had 
significantly reduced DFS (P < 0.005) but also had reduced OS (P=0.08).  
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Fig 16. Kaplan-Meier survival curves stratified by CLISA-determined PY1248 ErbB2 levels. Patients 
whose tumors contain high levels of PY1248 ErbB2 (above median value) show a significantly worse 
outcome. Significant differences in both in DFS and in OS curves. 
 
 
4.2.4. High PY1248 ErbB2 Levels are Associated With Reduced Tumor ER and PgR 
Content. Only 14% (5/35) of high PY1248 ErbB2 containing tumors were ER- negative 
(> 20 fmol/mg), and only 31% (11/35) PgR- negative (> 20 fmol/mg). In contrast, 43% 
(15/35) of low PY1248 ErbB2 containing tumors were ER- negative, and 63% (22/35) 
PgR-negative (Figure 17). Analysis of quantitative levels of PY1248 ErbB2 revealed 
inverse correlation with quantitative mRNA as well as protein expression levels of ER 
and PgR (Figure 18, Table 3).   
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Fig 17. Box-plot showing the dramatically reduced tumor ER and PgR protein levels in association with 
high levels of PY1248 ErbB2 (above median value). 
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Fig 18. Scatter plot of PY1248 ErbB2 versus ER expression levels. 
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4.2.5. Correlation of PY1248 ErbB2 Levels and mRNA expression levels of EGFR 
family members. Spearman rank correlation analysis of quantitative PY1248 ErbB2 
levels and quantitative mRNA expression levels of EGFR family receptors (detected by 
OncoScore, AG staff) was carried out. Comparison of ErbB family expression on mRNA 
level with ErbB2 phosphorylation revealed significant correlation with ErbB2 (rs=0.62, 
p<0.001) and EGFR (rs=0.26, p=0.05) (Table 3) and inverse correlation with ErbB3 (rs=-
0.22, p=0.08) and ErbB4 (rs=-0.47,  
p=0.0005) (Table 3).  
 
Table 3. Spearman rank correlation analysis of quantitative PY1248 ErbB2 levels and quantitative levels of 
EGFR family receptors, ER and PgR. 
PY1248 ErbB2 
Correlation  
With: 
Spearman correlation coefficients with 
respect to mRNA expression levels 
Spearman correlation 
coefficients with respect to 
protein expression levels 
ER -0.54 (p<0.001) -0.67 (p<0.001) 
PgR -0.46 (p<0.001) -0.45(p<0.001) 
EGFR 0.26 (p=0.05) 0.43 (p<0.005) 
ErbB2 0.62 (p<0.001) 0.53 (p<0.0005) 
ErbB3 -0.22 (p=0.08) n.d. 
ErbB4 -0.47(p=0.0005) n.d. 
 
 
4.2.6. Correlation of PY1248 ErbB2 Levels and protein levels of EGFR family 
members. Spearman rank correlation analysis of quantitative PY1248 ErbB2 levels and 
quantitative protein levels of EGFR and ErbB2 receptors was carried out. Significant 
correlation was found between EGFR levels, detected by EGF binding assay (rs=0.43, 
p<0.005) and PY1248 ErbB2 (Fig. 19, 20 and Table 3). Good agreement between 
PY1248 and ErbB2 levels, detected by EIA was found (rs=0.53, p<0.0005) (Table 3). 
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Fig 19. Scatter plot of PY1248 ErbB2 versus ErbB2 expression levels.  
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Fig 20. Scatter plot of PY1248 ErbB2 versus EGFR expression levels.  
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4.2.7. Correlation of mRNA Levels and Protein Levels of EGFR family members, 
ER and PgR. Spearman rank correlation analysis of quantitative mRNA levels and 
quantitative protein levels of EGFR, ErbB2, ErbB3, ErbB4, ER and PgR was carried out 
in order to see whether the correlations between protein expression and mRNA 
acceptable  . Good agreement was found for all factors used in this study (Table 4). 
 
Table 4. Spearman rank correlation analysis of quantitative mRNA levels and quantitative protein levels of 
EGFR, ErbB2, ER and PgR. 
Factor Spearman correlation coefficient between mRNA and protein expression 
levels 
ER 0.84 (p<0.001) 
PgR 0.72 (p<0.001) 
EGFR 0.48 (p<0.005) 
ErbB2 0.59 (p<0.001) 
 
 
4.3. Discussion.  
 
This is the first study analyzing the activation of ErbB2 in breast tumors in relation to the 
expression of EGFR family of receptor tyrosine kinases as well as other clinical – 
pathological variables and survival. We aimed to confirm our previous data on the 
prognostic role of PY1248 ErbB2 in patients overexpressing ErbB2 and on the other hand 
to assess the prognostic value of PY1248 ErbB2 in patients with intermediate levels of 
ErbB2. We also aimed to reveal probable relations between phosphorylation of ErbB2, 
and the expression levels of EGFR family members as well as hormone receptors. 
In this study, PY1248 ErbB2was considered positive in 50% of the tumors and it was not 
associated with nodal status or tumor size, but we did find a strong association with 
EGFR and ErbB2 expression and strong inverse correlation with ER, PgR and ErbB4 
expression. ErbB4 mRNA expression has been shown to be associated with good 
prognosis in a number of studies (199-201), supporting the inverse correlation with P-
ErbB2. There was also weak inverse correlation between PY1248 ErbB2 and ErbB3 
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expression. Since it has been observed that ErbB3 collaborates with ErbB2 in driving 
breast tumor cell proliferation (202), the negative association between PY1248 ErbB2 
and ErbB3 was unexpected. Nevertheless, ErbB3 mRNA expression has been shown to 
be associated with good prognosis in several studies (199-200), as well as in our 
collective (data not shown). Relationship between protein levels of ErbB3 and ErbB2 as 
well as phosphorylation of both factors could possibly better explain these discrepancies.  
It has been suggested by several studies that ErbB2 in a heterodimer with EGFR, is 
involved in signaling pathways that are required for a human breast cancer cell to become 
metastatic (203-204). Our data further supports the importance of EGFR/ErbB2 
heterodimer in breast cancer.  
We conclude that the phosphorylation of ErbB2 could be a factor to consider together 
with other tumor characteristics in predicting relapses of breast cancer. 
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5. The role of Akt phosphorylation in primary breast 
cancer 
 
5.1. Introduction. 
 
Akt/protein kinase B (PKB) is a serine/threonine protein kinase involved in mediating 
various biological responses including inhibiting apoptosis and stimulating cell 
proliferation (205-206). So far three mammalian isoforms of this enzyme are known: 
Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ (205). Akt1 is the predominant form in most 
tissues, whereas Akt2 is highly expressed  in insulin-responsive tissues and Akt3 is 
relatively high expressed in brain and testis (206). Akt1 was first discovered as cellular 
homolog of a viral oncogene v-Akt causing leukemia in mice (207). Akt is known to be 
activated by phosphoinositol 3 phosphates (PIP3), the products of PI3K activity (208), 
downstream of a wide range of receptors. Among these receptors the c-Met receptor 
(209), epidermal growth factor receptor (EGFR) family (210), fibroblast growth factor 
receptor (211), insulin growth factor receptor (IGF) (212), and platelet-derived growth 
factor receptor (PDGFR) (213) are found. In addition, Akt activity can be regulated by 
the PTEN tumor suppressor gene, which negatively regulates PIP3 levels (214). Akt1 is 
activated by phosphorylation, after PIP3 binding, on two critical residues: threonine 308 
(T308) and serine 473 (S473). Similar residues are highly conserved in Akt2 and Akt3 
(205-206). Several studies have found Akt2 to be amplified or overexpressed on mRNA 
level in primary tumors and cell lines (215-217). Overexpression of Akt2 protein was 
also described in a number of human carcinomas, such as colon, pancreatic and breast 
tumors (218-220). However, Akt2 activation by phosphorylation may have more 
important prognostic value than Akt2 amplification or overexpression. On the other hand, 
phosphorylated Akt1 and Akt3 could be as important as phosphorylated Akt2.  
To this date, several groups have investigated the phosphorylation of Akt in breast, 
prostate, colon and pancreatic tumors using immunohistochemical (IHC) methods (218; 
221-226). However, phosphorylation structures may be disturbed by formalin imbedding 
rendering specific antigen sites difficult to be recognized. Moreover, IHC gives only 
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semiquantitative results limiting statistical analysis. In contrast, enzyme immunoassays 
(EIA) have the advantage to yield highly reproducible results of continuous values.  
In the following investigation we applied a novel CLISA which allows to detect 
phosphorylated Akt1, 2 and 3 in well characterized primary breast tumor tissue samples 
of 156 breast cancer patients. 
 
5.2. Results.  
 
5.2.1. Tumor and Patient Characteristics. A collective of 156 cryopreserved (-80°C) 
and well characterized primary breast tumors was selected from our tumor bank 
according to the ErbB2 protein expression levels routinely detected at time of surgery in 
order to better investigate interactions between P-Akt and ErbB2. All patients underwent 
primary surgery before January 1996. 67 patients experienced a disease recurrence within 
the median follow-up time of 57 months (range 27-88 months). Sixty six patients (42%) 
were nodal negative and 90 (58%) nodal positive. Forty tumors (26%) were estrogen 
receptor (ER) negative. None of the patients received neoadjuvant therapy. Details on 
patients and tumor characteristics are summarized in Table 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 68
 
Table 5. Clinicopathological characteristics of the patients. 
Feature Number of patients (%) 
Patients enrolled 156 
Age 
 <40 
 40-60 
>60 
 
12(8) 
85(54) 
59(38) 
Histology type 
  Ductal 
  Lobular   
  Other   
 
109 (70) 
17 (11) 
30 (19) 
Tumor size 
  T1 
  T2 
  T3-4 
 
49 (31) 
90 (58) 
17 (11) 
Lymph-node status 
  Node-negative 
  Node-positive 
 
66 (42) 
90 (58) 
Histopathological grade 
  I + II 
  III 
  Not analyzed 
 
57 (37) 
86 (55) 
13 (8) 
Estrogen receptor (ER) 
  Positive (>20 fmol/mg) 
  Negative (≤ 20 fmol/mg) 
 
116 (74) 
40 (26) 
Progesterone receptor (PgR)   
  Positive (>20 fmol/mg) 
  Negative (≤ 20 fmol/mg) 
 
85 (54) 
71 (46) 
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5.2.2. Distribution of P-Akt Levels in Breast Cancer Cytosolic Fractions. CLISA 
quantified P-Akt levels ranged from 0 to 1.084 U/mg with a median of 0.1665 U/mg 
(mean 0.199 U/mg). As shown in figure 21 P-Akt levels have a normal distribution. 
There was no correlation between the levels of P-Akt and ErbB2. Moreover, no 
correlation was found between the levels of P-Akt and nodal status, estrogen receptor 
(ER) status, tumor size nor differentiation staging. 
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Figure 21. (A) Histogram showing distribution of CLISA-determined P-Akt expression levels in 156 
primary breast cancer samples. P-Akt levels ranged from 0 to 1.084 U/mg with a median of 0.1665 U/mg. 
(B) Scatter plot of P-Akt versus ErbB2 expression levels. No correlation was found between the levels of 
P-Akt and ErbB2. 
 
  
5.2.3. Prognostic Significance of P-Akt Levels. The prognostic value of P-Akt was 
investigated with respect to relapse free survival in the overall collective. Univariate Cox-
regression revealed a weak correlation between P-Akt expression levels and relapse-free 
survival (p<0.05). In order to visualize this result, we calculated an optimal cut-off value 
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for P-Akt by CART and plotted Kaplan-Meier survival curves stratifying the patients 
according to the P-Akt levels of their tumors (Figure 22). Out of the 21 patients (14% of 
all collective) with tumors expressing P-Akt levels higher than 0.31 U/mg, 14 patients 
relapsed within the observation time with a disease-free survival rate of 33% (CI: 17.5-
61%) significantly (p < 0.01) worse as compared to those tumors with lower P-Akt levels 
(DFS rate of 60%, CI: 67-40%).  
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Figure 22. Total collective. Kaplan-Meier survival curves stratified by P-Akt levels. Patients whose 
tumors contain high levels of P-Akt show a significantly worse outcome in respect to DFS (p<0.01). 
 
5.2.4. Prognostic Significance of P-Akt in a subset of ErbB2-overexpressing tumors. 
Although no correlation was found between P-Akt and ErbB2 expression, the prognostic 
impact of P-Akt in the subset of ErbB2-overexpressing tumors was more evident. The 
Kaplan-Meier curves in Fig. 23a reveal that patients outcome decreases significantly 
when tumors express P-Akt levels higher than the median value (p=0.005) and even more 
when P-Akt expression levels exceed the third quartile value (p<0.001), indicating a 
cumulative prognostic impact of these 2 biomarkers (Fig. 23b). 
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Figure 23. Subset of patients with ErbB2 overexpressing tumors. Kaplan-Meier survival curves 
stratified by median (A) and last quartile (B) values of P-Akt. Patients whose tumors express high levels of 
P-Akt show a significantly worse outcome in respect to DFS. 
 
5.2.5. Correlation of P-Akt Levels and mRNA expression of proliferation markers. 
The quantitative P-Akt protein levels were correlated by Spearman rank with the 
quantitative mRNA expression levels of more than 60 biomarkers involved in different 
biological processes (detected by OncoScore, AG staff), such as proliferation, hormone 
dependency, apoptosis, growth factors and angiogenesis. P-Akt expression levels were 
found to correlate only with proliferation makers. A good correlation was found with 
respect to thymidylate synthase (TS) (rs=0.38, p<0.001) (Figure 24), whereas the positive 
correlations found between P-Akt and thymidine kinase 1 (TK1) (rs=0.23, p<0.01), 
survivin (rs=0.22, p<0.01), topoisomerase II alpha (TOPO II alpha) (rs=0.19, p<0.05), and 
transcription factor E2F (rs=0.22, p<0.01) were less prominent. 
The P-Akt levels were also correlated by Spearman rank with the quantitative mRNA 
expression levels of more than 40 000 genes using DNA microarrays (carried out by Dr. 
Patrick Urban, using home-made DNA microarrays, ISREC, Laussane, Switzerland). 
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Correlation between numerous genes involved in Cell Cycle / Prolifereation and P-Akt 
was reconfirmed, as seen in Table 6. 
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Figure 24. Scatter plot of P-Akt versus TS mRNA expression levels. The strong significant correlation 
(rs=0.38, p<0.001) was found.  
 
 
5.2.6. Genes Associated with P-Akt. We have also carried out the comparison of gene 
expression in P-Akt positive vs P-Akt negative samples by Wilcoxon test using DNA 
microarrays.  The significant difference in expression levels of more than 25 genes was 
found, as shown in Table 7. Some other relevant genes, such as Akt1 and ErbB2 were 
close to being significant. 
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Table 6. Spearman rank correlation analysis of quantitative P-Akt levels with 25 Top Genes from Array. 
Spearman 
correlation (rs) Gene ChromLocation 
Description  
0.51 TYMS 18p11.32 thymidylate synthetase  
0.48 HMGB2 4q31 high-mobility group box 2  
0.38 KIF22 16p11.2 kinesin family member 22  
0.36 CENPF 1q32-q41 
centromere protein F, 
(mitosin)  
0.34 ZNF354A 5q35.3 zinc finger protein 354A  
0.34 RANBP17 5q34 RAN binding protein 17  
0.33 RAD54L 1p32 RAD54-like (S. cerevisiae)  
0.32 CDC2 10q21.1 
cell division cycle 2, G1 to S 
and G2 to M  
0.32 UHRF1 19p13.3 
ubiquitin-like, containing 
PHD and RING finger 
domains, 1  
0.32 ZNF200 16p13.3 zinc finger protein 200  
0.32 EZH2 7q35-q36 
enhancer of zeste homolog 2 
(Drosophila)  
0.32 CBX1 17q 
chromobox homolog 1 (HP1 
beta homolog Drosophila )  
0.31 DDX11 12p11 
DEAD/H (Asp-Glu-Ala-
Asp/His) box polypeptide 11  
0.31 CGI-01 1q24-q25.3 CGI-01 protein  
0.31 FEN1 11q12 
flap structure-specific 
endonuclease 1  
0.31 TP53BP2 1q42.1 
tumor protein p53 binding 
protein, 2  
0.31 SFRS1 17q21.3-q22 
splicing factor, 
arginine/serine-rich 1  
0.31 KIF20A 5q31 kinesin family member 20A  
0.31 LUC7L 16p13.3 LUC7-like (S. cerevisiae)  
0.30 PCNA 20pter-p12 
proliferating cell nuclear 
antigen  
0.30 STMN1 1p36.1-p35 stathmin 1/oncoprotein 18  
0.30 C16orf34 16p13.3 
chromosome 16 open reading 
frame 34  
0.30 CDC2 10q21.1 
cell division cycle 2, G1 to S 
and G2 to M  
0.30 MGC24665 16p13.2 
hypothetical protein 
MGC24665  
0.29 RAD51 15q15.1 
RAD51 homolog (RecA 
homolog, E. coli) (S. 
cerevisiae)  
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Table 7. Genes Associated with pAkt positive vs. pAkt negative. Thirty Top Genes from Array. 
p value Gene Name Chrom. 
Location 
Description  
0.0012 CHGB      20pter-p12      chromogranin B (secretogranin 1)                                                                                                                           
0.0078 LLGL2     17q24-q25       lethal giant larvae homolog 2 (Drosophila)                                                                                                                 
0.0118 C1orf29   1p31.1          chromosome 1 open reading frame 29                                                   
0.0218 APOE      19q13.2         apolipoprotein E                                                                                                                                       
0.0264 THRAP1    17q22-q23       thyroid hormone receptor associated protein 1                                                                                                              
0.0271 CYP4B1    1p34-p12        cytochrome P450, family 4, subfamily B, 
polypeptide 1                                                                                                      
0.0278 ARNT2     15q24           aryl-hydrocarbon receptor nuclear translocator 2                                             
0.0298 DHRS2     14q11.2         dehydrogenase/reductase (SDR family) member 
2                                                                                                              
0.0298 STIP1     11q13           stress-induced-phosphoprotein 1 (Hsp70/Hsp90-
organizing protein)                                                                                           
0.0348 GRIA2     4q32-q33        glutamate receptor, ionotropic, AMPA 2                                                                                                                     
0.0358 AREG      4q13-q21        amphiregulin (schwannoma-derived growth 
factor)                                                                                                            
0.0373 G22P1     22q13.2-q13.31  thyroid autoantigen 70kDa (Ku antigen)                                                                                                                     
0.042 KRT20     17q21.2         keratin 20                                                                                                                                                 
0.042 ZZEF1     17p13.3         zinc finger, ZZ-type with EF hand domain 1                                                                                                                 
0.0424 AGTR1     3q21-q25        angiotensin II receptor, type 1                                                                                
0.0447 SLC39A6   18q12.2         solute carrier family 39 (zinc transporter), 
member 6                                                                                                      
0.0458 CCL19     9p13            [e-value: 1.7e-87] chemokine (C-C motif) ligand 
19                                                                                                         
0.0481 IFI27     14q32           interferon, alpha-inducible protein 27                                                                                                                     
0.0491           NA              MRNA; cDNA DKFZp686F01160 (from clone 
DKFZp686F01160)                                                                  
0.05 C7        5p13            complement component 7                                                                                                                                     
0.05 SDC4      20q12           syndecan 4 (amphiglycan, ryudocan)                                                                                                                         
0.052 KRT16     17q12-q21       keratin 16 (focal non-epidermolytic palmoplantar 
keratoderma)                                                                                              
0.0538 MGC5395   11q12-q13       hypothetical protein MGC5395                                                                                                                               
0.0546 SDC4      20q12           syndecan 4 (amphiglycan, ryudocan)                                                                                                                         
0.0549 PSAP      10q21-q22       prosaposin (variant Gaucher disease and variant 
metachromatic leukodystrophy)                                                                              
0.0592 ERBB2     17q11.2-q12     v-erb-b2 erythroblastic leukemia viral oncogene 
homolog                                              
0.0605 SERPINB5  18q21.3         serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 5                                                                                   
0.0627 TPD52L1   6q22-q23        tumor protein D52-like 1                                                                                                                                   
0.0652 TCF20     22q13.3         transcription factor 20 (AR1)                                                                        
0.0703 AKT1      14q32.32        v-akt murine thymoma viral oncogene homolog 
1                                                                                                              
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5.3. Discussion 
 
This investigation demonstrates clearly that breast cancer patients with high levels of Akt 
phosphorylation (13.5%) have a significantly worse relapse free prognosis as shown in 
Fig. 21. No correlation was found between levels of P-Akt, ErbB2 expression levels, 
nodal Status, ER/PgR status, tumor size and/or  tumor differentiation.  
Similar results have been previously reported using IHC as standard method. Perez-
Tenorio et al. (221) demonstrated that bad prognosis was correlated with increased 
phosphorylation of Akt in endocrine therapy-treated patients, whereas Schmitz et al. 
(223) observed prognostic relevance of P-Akt in node-negative breast cancer and Stal et 
al. (222) showed that Akt activation is associated with decreased local benefit from 
radiotherapy.  
Our study is the first report on P-Akt assessment by EIA using a phospho-specific 
antibody in breast cancer cytosols of cryopreserved samples, since it was previously 
pointed out that assays performed on frozen tumor tissue allow more precise and 
quantitative results (227). In contrast to the semi-quantitative and partly subjective IHC 
data, tumor marker expression levels assessed by quantitative EIA measurements are 
more reliable with respect to sensitivity and reproducibility. Moreover, EIA results 
obtained from fresh frozen tissue extracts avoid the potential antigen damage due to 
formalin fixation, paraffin embedding and uncontrolled storage. Furthermore, the two-site 
(sandwich) CLISA assay used ensures increased specificity as compared to one-antibody 
assays such as IHC and Western Blotting. In addition chemoluminometric detection 
provides high sensitivity for the detection of antigen/antibody complex.  
  We assumed to find a correlation between ErbB2 and P-Akt, since ErbB2 has 
been implicated in the Akt activation (228). Nevertheless, Akt can be also activated by 
various other receptor tyrosine kinases (209-213), by G protein-coupled receptors (229), 
and by other molecules often deregulated in breast cancer. Loss of PTEN activity in 
breast cancer (230) is accompanied by increased expression of the activated form of Akt. 
Based on these findings it is clear that Akt can be activated by ErbB2 as well as by other 
stimuli. Therefore Akt activation has not to be necessarily correlated with ErbB2  
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overexpression  though we have shown that the prognostic significance of  P-Akt is 
increased if congruent with ErbB2 overexpression. 
Of interest is the correlation of P-Akt with mRNA expression levels of tumor 
proliferation markers we observed in this study. Akt is known to promote cell cycle 
progression by modulating the expression (231) and stabilization of cyclin D1 (232), 
which in turn activates the E2F transcription factor. Our results demonstrate a significant 
correlation of P-Akt with E2F transcription factor expression of as well as the expression 
of E2F-regulated genes, namely TS, TK, survivin and TOPO IIalpha (Fig. 25). 
 
 
 
 
Fig. 25. Schematic representation of Akt-induced cell cycle progression. Akt signaling pathway modulates 
the stabilization of cyclin D1, which in turn activates the E2F transcription factor as well as the expression 
of E2F-regulated genes. 
 
 
In conclusion, we were able to reconfirm that high levels of P-Akt is a marker of poor 
prognosis (decreased DFS), although Akt Phosphorylation is not associated with the 
nodal status of the patients or with other tumor characteristics including the ErbB2 status. 
E2F/pRb 
Akt 
p70s6k 
p21CIP1/WAF1 
CDK4/Cyclin D1 
pRb 
E2F TS  
TK 
TOPOII 
Survivin 
 77
Moreover, the prognostic value of P-Akt levels increased in the subset of patients with 
ErbB2-overexpressing tumors. In addition, the phosphorylation of Akt was found to be 
associated with the expression of tumor proliferation factors. Based on these results, we 
propose to investigate the predictive value of P-Akt with respect to Herceptin and 
topoisomerase inhibitor therapy. Lastly, we suggest combination therapies with Akt 
inhibitors in a subset of well-characterized human breast tumors. 
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6. Analysis of ErB2, ShcA and Akt phosphorylation in 
primary breast cancer 
 
6.1. Introduction. 
 
Molecular analysis of human tissue specimens is performed for diagnostic and 
prognostic purposes. Morphologic examination provides complex visual information 
about cell and tissue characteristics, whereas molecular analysis provides valuable data 
about the expression of individual proteins or genes. The most common method for 
extracting molecular information from human tissues is to visualize protein levels in 
tissue either by immunohistochemistry or EIA approaches. This analysis, however, 
remains limited in its ability to elucidate the function of such proteins. Protein function is 
regulated not only by transcription and translation, but also by such posttranslational 
modifications as phosphorylation, glycosylation, and prenylation. The most reversible of 
these modifications is phosphorylation, a reaction that involves transfer of a nucleotide 
phosphate to recipient tyrosine or serine/threonine amino acid. This mechanism lies 
behind most pathways cell signal transduction and is thus fundamental both normal 
physiology and disease. Given these considerations, the number of proteins in the 
activated (phosphorylated) state may be more important biologically than the total 
number of proteins present. We therefore assumed that protein phosphorylation 
(indicative of signaling activity), either in addition to or rather than protein 
overexpression data, might improve the prognostic value. 
ErbB2 is a 185 kDa oncoprotein (p185), which is overexpressed in 25–30% of 
invasive breast cancers. Intracellular phosphorylated tyrosine residues of the ErbB2 
molecule function as high-affinity binding sites for SH2 domain containing proteins, 
which link the receptor to intracellular signal transduction pathways such as the Ras-Raf- 
MAPK and the PI3K-Akt pathways. Both are believed to be key elements in the 
regulation of cell proliferation and survival (233). In this context, phosphorylation of the 
Y1248, which is supposed to constitute main autophosphorylation site of ErbB2, is a key 
event for downstream signalling (234), followed by the phosphorylation of other 
autophosphorylation sites, namely Y1023, Y1139, Y1196 and Y1121/1122.   Receptor 
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tyrosine kinase signalling may be physiologically terminated either by homologous 
receptor desensitization to the continued presence of ligand, or else via heterologous 
receptor transmodulation by other ligand-activated tyrosine kinases. The best  
desensitization studies has been performed on the EGFR. On each side of the EGFR 
catalytic domain lies a desensitization domain: the juxtamembrane region containing the 
Thr654 PKC site (235-237), and the carboxyterminal SH2-like domain containing 
Ser1046/7 the calcium/calmodulin-dependent kinase II (CamKII) site (238). Like the 
EGFR, desensitization of the ErbB2 tyrosine kinase is mediated through phosphorylation 
of serine and threonine residues within the intracellular part of the receptor (101). 
Akt/PKB is a central signaling serine/threonine kinase that has been implicated in the 
genesis or progression of numerous human tumors, because it regulates many of the key 
effector molecules involved in apoptosis, anoikis and cell cycle progression (205). 
Activation of the Akt pathway suppresses apoptotic response, undermines cell cycle 
control and selectively enhances the production of key growth and survival factors. Upon 
stimulation, Akt is recruited to the plasma membrane through the binding of its N-
terminal pleckstrin homology (PH) domain to PIP3, a lipid product of PI3K (208). Akt is 
then activated by phosphorylation on two residues: Thr-308 in the activation loop and 
Ser-473 in the hydrophobic motif of the C-terminal tail. 
 The adapter protein Shc is a SH2 containing proto-oncogene involved in growth 
factor signaling. In addition to the ubiquitously expressed ShcA, two other isoforms, 
ShcB and ShcC exist, which are expressed in neuronal cells ShcA in vivo. Based on 
molecular and mouse knock-out studies major role for ShA leading to MAPK activation 
has been established (120-121). ShcA is expressed as three splice forms of about 
46, 52 and 66 kDa. Within the CH domain of ShcA, three tyrosine-phosphorylation sites 
have been identified. The Y239/Y240 twin tyrosines have been linked to c-Myc 
activation (239-240); however, the mechanism by which Shc leads to c-Myc activation is 
not known. Y317 tyrosine has been established in leading to MAP kinase activation 
through Grb2 and Sos (241). The p66Shc possesses an additional CH2 domain that 
contains a serine phosphorylation site that has been implicated in oxidative stress 
signaling (242). 
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 We applied  novel two-site CLISA assays, which allowed us to detect Y, S and T 
phosphorylated ErbB2, Y and S phosphorylated ShcA and S473 phosphorylated Akt1, 2 
and 3 in well characterized primary breast tumor tissue samples of 153 breast cancer 
patients.  
 
 
6.2. Results.  
 
 
6.2.1. Tumor and Patient Characteristics. A collective of 153 cryopreserved (-80°C) 
and well characterized  primary breast tumors was selected from our tumor bank 
according to the ErbB2 and ER protein expression levels routinely detected at time of 
surgery. 80 (52%) tumors overexpressed ErbB2, the remaining 73 (48%) had 
intermediate (100-260 ng/mg) levels. Ninety eight tumors (64%) were estrogen receptor 
(ER) negative, the remaining 55 (36%) had low (20-50 fmol/mg) ER levels. All patients 
underwent primary surgery before January 1996. Seventy seven (50%) patients 
experienced a disease recurrence within the median follow-up time of 47 months (range 
24-87 months). Seventy five patients (49%) were nodal negative and 58 (38%) nodal 
positive. None of the patients received neoadjuvant therapy. Details on patients and 
tumor characteristics are summarized in Table 8. Due to the fact that tumors we selected 
for this study were mostly aggressive tumors (high ErbB2, low ER, nodal positive, 
relapsing tumors), it was impossible to analyze the prognostic value of the molecules 
studied. 
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Table 8. Clinicopathological characteristics of the patients. 
Feature Number of patients (%) 
Patients enrolled 153 
Age <40 
        40-60 
       >60 
10 (6.5) 
88 (57.5) 
55 (36) 
Histology type 
  Ductal 
  Lobular   
  Other   
 
104 (68) 
9  (6) 
40 (26) 
Tumor size 
  T1 
  T2 
  T3-4 
  Unknown 
 
39 (25) 
87 (57) 
24 (16) 
3  (2) 
Lymph-node status 
  Node-negative 
  Node-positive 
 Unknown 
 
58 (38) 
75 (49) 
20 (13) 
Histopathological grade 
  I + II 
  III 
  Not analyzed 
 
49 (32) 
57 (37) 
47 (31) 
Estrogen receptor (ER) 
  Positive (>20 fmol/mg) 
  Negative (≤ 20 fmol/mg) 
 
55 (36) 
98 (64) 
Progesterone receptor (PgR) 
  Positive (>20 fmol/mg) 
  Negative (≤ 20 fmol/mg) 
 
40 (26) 
113 (73) 
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6.2.2. Distribution of PY, PS and PT ErbB2 Levels in 153 Breast Cancer Membrane 
Fractions. CLISA quantified PY ErbB2 levels ranged from 0 to 1000 U/mg with a 
median of 3.72 U/mg (mean 54.49 U/mg). Increased levels PY ErbB2 were found in 
ErbB2 - overexpressing tumors, median 6.39 U/mg (mean 86.28 U/mg) as compared to 
low-ErbB2-expressing tumors, median 2.06 U/mg (mean 19.66 U/mg), which 
reconfirmed the PY1248 ErbB2 result (Fig. 26). CLISA quantified PS ErbB2 levels 
ranged from 0 to 198.64 U/mg with a median of 0 U/mg (mean 5.85 U/mg). No PS 
ErbB2 was detected in ErbB2 - overexpressing tumors. In a subpopulation of low-ErbB2-
expressing tumors, median of PS ErbB2 levels was 5.7 U/mg (mean 12.18 U/mg) (Fig 
27). CLISA quantified PT ErbB2 levels ranged from 0 to 1000 U/mg with a median of 0 
U/mg (mean 0.15 U/mg). As in the case of PS ErbB2, no PT ErbB2 was detected in 
ErbB2 - overexpressing tumors. In a subpopulation of low-ErbB2-expressing tumors, 
median of PT ErbB2 levels was 0 U/mg (mean 0.32 U/mg). (Fig. 28). 
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Fig 26.  Histogram showing distribution of EIA-determined  ErbB2 expression levels in total collective of 
153 primary breast cancer samples (A), CLISA-determined  PY1248 ErbB2 expression levels in total 
collective (B), and subpopulation of erbB2-overexpressing tumors (C) and subpopulation of low-erbB2 
expressing tumors (D). 
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Fig 27.  Histogram showing distribution of CLISA-determined  PS 1248 ErbB2 expression levels in total 
collective of 153 primary breast cancer samples (A) and subpopulation of low-erbB2 expressing tumors 
(B).
 
 
 
 
 
Fig 28.  Histogram showing distribution of CLISA-determined  PT 1248 ErbB2 expression levels in total 
collective of 153 primary breast cancer samples (A) and subpopulation of low-erbB2 expressing tumors 
(D). 
 
 
6.2.3. Correlation of PY, PS and PT ErbB2 Levels and ErbB2 expression levels. 
Spearman rank correlation analysis of quantitative PY, PS and PT ErbB2 levels and 
quantitative ErbB2 expression levels was carried out. Comparison of ErbB2 expression 
on protein level with ErbB2 phosphorylation revealed significant correlation with PY 
ErbB2 (rs=0.33, p<0.001) and EGFR (rs=0.26, p=0.05) and inverse correlation with PS 
ErbB2 (rs=-0.53, p<0.01) (Figure 29, Table 9). There was no significant correlation 
between ErbB2 expression and PT ErbB2 levels. 
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Fig 29. Scatter plot of PY ErbB2 versus ErbB2 expression levels (A), PS ErbB2 versus ErbB2 expression 
levels (B) and PT ErbB2 versus ErbB2 expression levels (C).   . The strong significant correlation (rs=0.33, 
p<0.01) was found between  PY ErbB2 and ErbB2 expression and significant inverse correlation (rs=-0.53, 
p<0.01) was found between PS ErbB2 and ErbB2 expression. 
 
6.2.4. Distribution of PY and PS ShcA Levels and PS473 Akt in Breast Cancer 
Membrane Fractions. CLISA quantified PY SchA levels ranged from 0 to 32.33U/mg 
with a median of 4.05 U/mg (mean 4.63 U/mg) and PS SchA levels ranged from 0 to 
19.49 U/mg with a median of 3.76 U/mg (mean 4.27 U/mg) (Figure 30). 
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Fig 30.  Histogram showing distribution of CLISA-determined  PY SchA (A) and  PS SchA (B) levels in 
total collective of 153 primary breast cancer samples. 
 
6.2.5. Correlations between PY, PS and PT ErbB2, PY and PS ShcA and PS473 Akt. 
The quantitative PY, PS and PT ErbB2, PY and PS ShcA and PS473 Akt protein levels 
were correlated by Spearman rank . Good correlation was found between PS ErbB2 and 
PT ErbB2(rs=0.74, p<0.01), PS ShcA and PY SchA (rs=0.88, p<0.01), PT ErbB2 and 
ER(rs=0.34, p<0.01), and  PT ErbB2 and PgR(rs=0.39, p<0.01),  (Figure 31, Table 9), 
whereas the positive and/or inverse correlations found between other factors  were less 
prominent or even insignificant (Table 9). 
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Fig 31. Scatter plot of PS ErbB2 versus PT ErbB2  levels (A), PS ShcA versus PT ShcA  levels (B), PT 
ErbB2 versus ER expression levels (C) and PT ErbB2 versus PgR expression levels (D).  
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Table 9. Spearman rank correlation analysis of quantitative PY, PS and PT ErbB2, PY and PS ShcA and 
PS473 Akt. 
  PY ErbB2 PS ErbB2 PT ErbB2 P Akt PY ShcA PS ShcA 
ErbB2 rs=0.33 rs=-0.53 n.s. n.s. n.s. rs=0.18 
ER n.s. rs=0.20 rs=0.34 n.s. n.s. n.s. 
PgR n.s. rs=0.27 rs=0.39 n.s. n.s. n.s. 
PY ErbB2 ________ n.s. rs=0.26 rs=0.20 n.s. n.s. 
PS ErbB2 n.s. _________ rs=0.74 n.s. n.s. n.s. 
PT ErbB2 rs=0.26 rs=0.74 __________
_ 
rs=0.18 rs=0.27 rs=0.21 
P Akt rs=0.20 n.s. rs=0.18 _______ rs=-0.27 rs=-0.28 
PY ShcA n.s. n.s. rs=0.27 rs=-0.27 _________ rs=0.88 
PS ShcA n.s. n.s. rs=0.21 rs=-0.28 rs=0.88 _________ 
 
 
 
6.3. Discussion 
 
Our study is the first report on assessment of pan S, T and Y phosphorylation of ErbB2 
and S and T phosphorylation by EIA using a phospho-specific antibody in breast cancer 
cytosols of cryopreserved samples.  
It has been reported that differentially phosphorylated ErbB2 isoforms vary in such 
functional features as ligand-dependent catalytic activity (243-244), heterodimerization 
(245-246), down-regulation kinetics (246-247), and intracellular trafficking (245, 248). 
Having shown in this report that patterns of site-specific phosphorylation differ between 
cancer patients, it is reasonable to infer that ErbB2 may not have an identical role in all 
tumors. However, quite clear prevalence of PY ErbB2 in ErbB2 overexpressing tumors 
could be seen both from the results this study as well as the PY 1248 assessment. 
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Consistent with this is preliminary data showing an association between ErbB2 kinase 
activity, and PY ErbB2 immunoreactivity (243, 249). 
Interestingly, PS and PT ErbB2 was not detected in ErbB2 overexpressing tumors, but 
quite high levels could be detected in low ErbB2 expressing tumors. This data is 
consistent with the fact that desensitization of the ErbB2 kinase activity is mediated 
through phosphorylation of serine and threonine residues of the receptor via PKC (248). 
Moreover PT and PY ErbB2 strongly correlates with ER and PgR protein levels, further 
inferring the “opposing” function of serine and threonine phosphorylation.  PT and PS 
ErbB2 levels correlated very well with each other, suggesting similar function and/or 
regulation. 
It has been reported, that all EGFR family members have docking sites for ShcA binding 
either via SH2 or PTB domains (250), therefore it was not very surprising that ShcA 
phosphorylation did not correlate significantly neither with ErbB2 expression nor with 
it’s phosphorylation. However, significant, although weak correlation was found with PT 
ErbB2 levels.  
Unfortunately, clinical outcome in this analysis could not be carried out due to the 
selection of the collective used in present study. The criteria used to select the collective 
(high or moderate ErbB2 levels and low ER levels), resulted in selection of highly 
aggressive subset of tumors, which made survival analysis impossible to be performed. In 
order to further continue analysis in order to investigate the prognostic role of pan-
phosphorylations of ErbB2 and ShcA different collective of tumors should be used, 
selected upon different criteria or just a collective of randomly selected samples. 
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7. Discussion and Perspectives 
 
Since the value of ErbB2 (HER-2/neu) analysis for prognosis or prediction has been 
controversial, our goal was to determine whether ErbB2 signaling improved the 
prognostic power of ErbB2 analyses. Prognostic significance of Y1248-phosphorylated 
ErbB2 has been previously investigated by several groups including ours (), in both fixed 
and unfixed tissues using a variety of methods. We have also shown that PY1248 ErbB2 
is detectable in only in a minority of ErbB2–overexpressing breast cancers. 
In the present study, we found site-specific receptor phosphorylation to be more prevalent 
among ErbB2–positive cases (18%) than among ErbB2–negative cases (5%). In the entire 
study population PY1248 ErbB2 data provided more valuable prognostic information 
than ErbB2 expression data.  
Our study population was not part of any particular clinical protocol and they were not 
uniformly treated. This excludes analyses of interactions between PY1248 ErbB2 and 
therapy.  
Because of the expected relationship of phosphorylation and PY1248 ErbB2 positivity 
with high-level overexpression in general, it could be considered that PY1248 ErbB2 
positivity could simply be a surrogate for high-level overexpression, especially due to the 
fact that in previous studies in patients which expressed low and moderate levels of  
ErbB2, PY1248 ErbB2 immunopositivity was not observed. However, using particularly 
sensitive CLISA assay, we could detect PY1248 ErbB2 in patients which expressed  
moderate levels of  PY1248 ErbB2. This observation was confirmed in a different study, 
using pan-PY antibody. Unfortunately predictive value of pan-PY ErbB2 as well as pan-
PS and pan-PT ErbB2, could not be carried out in the collective used for this study and 
therefore has to be repeated in a different, randomly selected collective. On the other 
hand, the number of patients used for a PY1248 study was small (n=70), reducing the 
power of the study and making firm conclusions difficult to draw. Therefore PY1248 
ErbB2 should be assessed in a larger subset of well characterized breast tumors (n>100).  
ErbB2 testing is most commonly applied because of its value as a predictive factor, either 
for consideration for trastuzumab treatment or because of interactions between 
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ErbB2 and other chemotherapeutic agents. Thus PY ErbB2 has to be evaluated in order to 
determine whether it is predictive of response to trastuzumab, doxorubicin, or tamoxifen. 
 
We have also performed the first EIA study analyzing the activation of Akt in breast 
tumors in relation to other clinico – pathological variables and survival. We aimed to 
investigate whether this molecule, found in vitro to play a important role in oncogenesis 
showed the same significance in clinical material. 
Our study demonstrates that breast cancer patients with high levels of Akt 
phosphorylation have a significantly worse disease free survival. We could not find any 
significant association of P-Akt with nodal status, tumor size, ER, PgR or other clinico – 
pathological features, including ErbB2 expression. On the other hand  we have shown 
that the prognostic significance of  P-Akt is increased if congruent with ErbB2 
overexpression. Based on that, P-Akt should be investigated in a larger subset of ErbB2 
overexpressing breast tumors (n>100), assessing not only the prognostic value but also 
the predictive value of P-Akt with respect to Herceptin therapy. On the other hand it 
remains to be elucidated phosphorylation of which Akt isoform plays the principal role. 
Therefore the phosphorylation and/or expression of the individual Akt isoforms should be 
assessed, if possible, in the same collective of tumors as total P-Akt.  
Of particular interest are the correlation of P-Akt with tumor proliferation markers as 
well as the correlation of PY 1248 ErbB2 with EGFR and inverse correlation with ErbB4 
mRNA expression levels that we observed in this study. The biology behind these 
correlations could be further investigated using tissue culture and/or animal models. The 
weak inverse correlation of ErbB2 with ErbB3 mRNA expression levels is arguing 
against the tissue culture – based findings and should be further investigated. Protein 
expression levels of ErbB3 and phosphorylation of ErbB3 should be assessed in the 
samples previously tested for ErbB2 expression as well as PY 1248 ErbB2 contents. 
Protein levels of ErbB3 (and P-ErbB3) should be evaluated both with respect to survival 
as well as ErbB2 (and P-ErbB2) status.  
As in the case with pan-P-ErbB2 study, the predictive value of pan-PY SchA and pan-PS 
ShcA could not be evaluated and therefore has to be repeated in a different collective. 
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Although many questions remain unanswered, assuming that the above mentioned tasks 
can eventually be achieved, our findings raise the exciting possibility of molecular 
diagnostics with improved application to rational therapeutic decision making and 
eventually to target-specific drug development. 
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List of abbreviations 
 
AP      alkaline phosphatase 
ATP      adenosine triphosphate 
CamK      calmoduline kinase 
CART     classification and regression trees 
CLISA      chemoluminescence linked immunosorbent assay  
CMF      cyclophosphamide, methotrexate and 5-fluorouracil 
DCIS     ductal carcinoma in situ 
ECL     enhanced chemoluminescense 
EGFR      epidermal growth factor receptor 
 EIA     enzyme immunoassays 
ELISA     enzyme-linked immunosorbent assay 
ER     estrogen receptor 
Erk      extracellular signal regulated kinase 
FGF      fibroblast growth factor 
FGFR     fibroblast growth factor receptor,  
FGFR     fibroblast growth factor receptor 
FISH     fluorescent in situ hybridization 
GDP     guanosine diphosphate 
GSK3     glycogen synthase kinase 3 
GTP     guanosine triphosphate 
HM  
HRP     horseradish peroxidase  
IFG-1     insulin-like growth factor 1 
IGFR     insulin-like growth factor receptor 
 IHC     immunohistochemistry  
JAK     Janus kiase 
JM     juxtamembrane 
kDa     kilodalton 
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LCIS     lobular carcinoma in situ, 
MAPK     mitogen-activated protein kinase 
MAPKAP    MAP kinase activated protein kinase 
MAPKK    MAP kinase kinase 
mRNA     messenger ribonucleic acid 
mTOR     mammalian target of rapamycin 
NFκB     nuclear factor κB 
NGFR     neuronal growth factor receptor 
PAI-1      plasimnogen activator inhibitor 
P-Akt      phosphorylated Akt 
PCR     polymerase chain reaction 
PDGFR    platelet - derived growth factor receptor 
PDK-1     phosphoinositol-dependent kinase 1 
 PgR     progesterone receptor  
PH     plecstrin homology 
PI3K     phosphoinositol-3 kinase 
PIP3     phosphoinositol 3 phosphate 
PKB     protein kinase B  
PKB     protein kinase B 
PLC     phospholipase C 
PS     phosphorylated serine 
PT     phosphorylated threonine, 
PTB     phosphotyrosine binding domain, 
PTEN      phosphatase and tensin homolog on chromosome 10 
PTK     protein tyrosine kinase, 
PY     phosphorylated tyrosine, 
Q-RT-PCR    quantitative reverse transcription PCR 
RLU     relative luminescence 
RTK     receptor tyrosine kinase 
S     serine 
PAGE     polyacrylamide gel electrophoresis 
 95
SH2     Src homology 2 
SDS     sodium duodecyl sulphate 
STAT     signal transducer and activator of transcription 
STB     Stiftung Tumorbank Basel  
T     threonine 
TK1      thymidine kinase 1  
TOPO II alpha    topoisomerase II alpha  
TS       thymidylate synthase 
uPA      urokinase-type plasminogen activator 
VEGFR     vascular endothelial growth factor receptor 
Y      tyrosine 
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Appendix 1. Schemes of sandwich CLISA assays 
 
 
      Figure 1. General layout of sandwich CLISA assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. The layout of the immunoassay for P-Y1248 ErbB2 detection 
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      Figure 3. The layout of the immunoassay for pan-P-Y ErbB2 detection 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 4. The layout of the immunoassay for pan-P-S ErbB2 detection 
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Figure 5. The layout of the immunoassay for pan-P-T ErbB2 detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 6. The layout of the immunoassay for P-S473 Akt detection 
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 Figure 7. The layout of the immunoassay for pan-P-Y ShcA detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Figure 8. The layout of the immunoassay for pan-P-S ShcA detection 
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Appendix 2. PKCε in prostate cancer 
 
Experiments were performed during 8.1999-5.2000 in Department of Anatomy and 
Cell Biology at East Carolina School of Medicine, under supervision by Prof. 
David M. Terrian, in collaboration with Dr. Daqing Wu. 
 
Introduction. 
 
Prostate cancer is the most frequently diagnosed cancer in men, accounting for 30% of all 
cancers, and is second leading cause of cancer deaths in men after lung cancer. In 2003, 
an estimated 220,900 American men were diagnosed with prostate cancer, and 
approximately 28,900 men died from the disease (1). Current methods of diagnosis 
including screening for high serum levels of prostate-specific antigen (PSA) and 
pathological grading of prostate biopsies cannot precisely distinguish between clinically 
aggressive and clinically indolent forms of prostate cancer. Therefore, far too many men 
are treated for the disease. Thus, there is an urgent need to identify biomarkers that 
distinguish the clinically aggressive forms of the tumor from the clinically indolent ones. 
Prostatic epithelia normally depend on a functional androgen receptor (AR) signaling 
pathway for survival and undergo apoptosis in response to androgen ablation therapy (2). 
This accounts for the clinical regression such treatments initially produce among prostate 
cancer patients treated by endocrine therapies. However, a relapse of tumor growth is 
common, and these recurrent tumors are androgen-independent, highly metastatic, and 
hardly responsive to chemotherapy (3). Thus, oncogenic proteins that actively maintain 
the growth and survival of prostate cancer cells after androgen ablation make evident 
targets for the treatment of advanced prostate cancer. Many laboratories have attempted 
to identify these proteins through comprehensive analyses of differential gene expression 
between androgen-dependent and androgen-independent prostate cancer cell lines and 
prostate cancer biopsies (4, 5). Nevertheless, there is currently no direct evidence to 
support the concept of a dominant oncogene in recurrent prostate cancer.  
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The role of the ErbB2 receptor remains uncertain in the pathogenesis and progression of 
human prostate cancer. Several studies have reported widely divergent rates for ErbB2 
expression in primary prostate tumors, probably owing to significant methodological 
differences in the studies (6, 7). Few data exist about the frequency of ErbB2 protein 
overexpression and gene amplification in androgen-independent prostate cancer, although 
xenograft models suggest ErbB2 expression may be up-regulated in the transition from 
androgen-dependent to androgen-independent disease (8). It has been shown that ErbB2 
could induce AR transactivation at a low androgen level in two different prostate cancer 
cell lines, LNCaP and DU145 (9). Furthermore, transfection of ErbB2 in LNCaP resulted 
in higher expression of prostate-specific antigen (PSA) and higher proliferating rate. The 
data also suggested the ErbB2 could potentiate the expression of AR target genes through 
the MAP kinase pathway, possibly through direct AR phosphorylation. 
PKCε is a member of the AGC family of Ser/Thr protein kinases that is known to have 
oncogenic potential (10) and to be associated with the progression of many cancers (11-
14). Although there is recent evidence that PKCε expression is elevated in tissue biopsies 
collected from prostate cancer patients (15), the role of this isozyme in the progression to 
androgen independence has not been investigated. The activation of PKCα and PKCδ 
induces apoptosis in LNCaP cells, an intensively studied androgen-sensitive prostate 
cancer cell line, but not androgen-independent (DU145 and PC3) prostate cancer cell 
lines (16-18). This finding indicates that at least some members of this gene family are 
capable of differentially regulating the growth and survival of prostate cancer cells. Given 
the reciprocal functions of PKC isozymes in various cell types (10) and the oncogenic 
activity of PKCε, we hypothesized that this isozyme may oppose the proapoptotic 
influence of PKCα and PKCδ in prostate cancer.  
In the present study, investigation of human prostate cancer cell lines indicated a 
relationship between PKCε expression and androgen independence. To better understand 
whether the expression of PKCε could be of functional importance in prostate cancer 
progression, we stably transfected LNCaP cells with a retroviral vector containing PKCε 
cDNA. This analysis revealed that PKCε overexpression was sufficient to transform 
LNCaP cells into an androgen-independent variant that rapidly initiated tumor growth in 
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both intact and castrated male nude mice. The investigation also revealed that PKCε 
could potentiate androgen independence through the MAP kinase pathway. This study 
provides data demonstrating that PKCε expression may contribute to recurrent tumor 
growth in the absence of testicular androgens.  
Materials and Methods. 
Materials. [3H]Thymidine (5 Ci/mmol) was obtained from Amersham (Piscataway, NJ, 
USA). PD098059 and LY294002 were from Sigma (St. Louis, MO, USA). Lipofectin 
and G418 were from Life Technologies (Carlsbad, CA, USA). 
Cell Lines and Culture Conditions. LNCaP cell line was obtained from American 
Type Culture Collection (Manassas, VA; ATCC CRL-1740). All cell culture reagents 
were
 purchased from Invitrogen (Rockville, MD). LNCaP cells were maintained in 
culture in RPMI 1640 containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium 
pyruvate, 4.5 g/l glucose, and 1.5 g/l sodium bicarbonate and supplemented with 10% 
FBS and 100 units/ml penicillin and 100 mg/ml streptomycin. Where indicated, cells 
were cultured in serum-free medium or in medium in which CS-FBS (Hyclone, 
Logan, UT) was substituted for untreated FBS. Cellular proliferation was assessed by 
the number of viable cells, which were counted, in triplicate, using a hemacytometer 
and trypan blue staining. Each assay was performed in triplicate in at least three 
independent experiments. 
Generation of Overexpressing Cell Lines- LNCaP cells were infected with pLXSN 
recombinant retrovirus (LNCVa) or pLXSN harboring the gene for PKCε (LNW) 
Plasmid pLXSN constructs were transfected into the amphotrophic packaging line 
PA317 using Lipofectin and selecting with 400 µg/ml G418. The titer of the resulting 
retrovirus was amplified by sequential passage between the ψ2 and PA317 packaging 
cell lines before infection of LNCaP cells as described in Ref. 19. Stably expressing 
cells were selected and subcloned by limiting dilution (20) in 500 µg/ml G418, and 
resultant subclones were then screened for PKCε protein expression by Western blot 
analyses and representative clones were used for further studies. 
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Assessment of in Vivo Tumor Growth. Intact and surgically castrated nude male 
mice (NU/NU-nuBR) were purchased from Charles River Laboratories (Wilmington, 
MA) and inoculated subcutaneously, into the dorsal flanks left and right of the 
midline, with 1 x 106 cells suspended in 250 µl of PBS/site and routinely inspected for 
tumor growth and morbidity for up to 10 weeks. Cell cultures used in these studies 
were
 free of Mycoplasma contamination. Solid tumor volumes were calculated by the 
formula: length x width x depth x 0.5236.  
[3H]Thymidine Incorporation Assays—Proliferation was evaluated by 
[3H]thymidine incorporation (at time 24 h). Cells (2 × 105/dish) were labeled for 12 h 
with [3H]thymidine (0.5 µCi/ml) before harvesting and then washed three times with 
PBS; after addition of 3% perchloric acid, the acid-precipitable material was 
dissolved overnight in 1 N NaOH, 1% SDS and counted by liquid scintillation 
(Packard Tricarb 4530 counter). 
Data Analysis. Values shown are representative of three or more experiments, unless 
otherwise specified, and treatment effects were evaluated using a two-sided Student’s 
t test. Errors are SEs of averaged results, and values of P < 0.05 were taken as a 
significant difference between means.  
 
Results. 
 
PKCε Causes Androgen-independent Growth and Tumorigenicity. To determine 
whether signals transduced through PKCε had the potential to contribute to the androgen-
idependent progression of prostate cancer, LNCaP cells overexpressing PKCε were 
established using the pLXSN retroviral vector. The pooled population of PKCε 
overexpressing LNCaP cells (LNW) were selected for by their collective resistance to 
G418, and a representative subclones (LNWa, LNWc) were isolated from this pool of 
transfectants by limiting dilution and maintained in culture. The pLXSN vector control 
line was called LNVa. LNWa, LNWc cells expressed equivalent levels of PKCε  and, 
compared with parental and vector controls, the catalytic activity of PKCε was increased 
(not shown).  
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When cultured in complete medium, LNCaP cells maintained a functional androgen 
receptor signaling pathway and gradually became arrested in G1 upon androgen removal 
(not shown). The overexpression of PKCε dramatically altered this phenotypic response 
to androgen withdrawal and enabled LNCaP cells to proliferate in the absence of 
androgens (Fig. 1). LNCaP cells overexpressing PKCε (LNW) remained responsive to the 
growth-promoting effects of DHT (Fig. 2). These results prompted investigation into the 
effects of PKCε overexpression on the tumorigenicity of LNCaP cells in the absence and 
presence of testicular androgens 
 
 
 
 
Figure 1. Growth of LNWa ( ), LNWc ( ) cells in charcoal treated medium (CS-FBS) and LNWa  
( ), and LNWc ( ) cells in normal medium (FBS). Cell proliferation was measured by counting the 
total number of viable cells/plate by trypan blue exclusion using the hemacytometer. Data are the 
means of triplicate determinations in three independent experiments. 
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Figure 2. Growth-promoting effects of increasing concentrations of DHT on LNW cells incubated at 
37°C for 3 days in CS-FBS. Cells were serum starved overnight before the introduction of DHT, and 
cell proliferation was measured by counting the total number of viable cells/plate by trypan blue 
exclusion. Data are the means of triplicate determinations in three independent experiments. 
 
 
PKCε overexpressing cells rapidly initiate tumor growth in nude mice. Mycoplasma-
free LNWa and LNWC cells (1 x 106/site) were injected subcutaneously into intact and 
castrated male nude mice. Matrigel was not used as an adjunct in any of these 
experiments, and all cells were injected alone as a suspension in PBS. Within 3–4 weeks, 
tumors appeared with a take rate of 100%, and the onset of tumor growth was more rapid 
in castrated animals (Table 1). No tumors formed during a 10-week observation period 
when an equal number of LNCaP cells were injected without Matrigel into intact and 
castrated male nude mice (Table 1). 
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Table 1. Intact and castrated male nude mice were injected subcutaneously with 1 x 106 LNCaP, 
LNWa or LNWc cells suspended in 0.25 ml of PBS. Data are the percentage of mice, which formed 
tumors for each group of eight mice. 
 
 
 
Mitogen activated protein kinase (MAPK) is the downstream mediator PKCε 
mitogenic signal, leading to androgen-independence. PKCε has been implicated in a 
receptor tyrosine kinase (RTK) downstream signaling both via PI3K and Ras pathways 
(Fig. 3). ErbB2 is an RTK known to affect prostate cancer growth as well as androgen-
independence via Ras/MAPK pathway. To determine whether MAPK cascade plays a 
role in androgen-idependent progression of prostate cancer mediated through PKCε LNW 
cells were treated with MEK-1 inhibitor PD098059. In order to rule out a possible direct 
effect of MAPK on proliferation of LNW cells, the difference between cells grown in 
FBS and CS-FBS was investigated.  
A significant reduction in proliferation of cells treated with PD098059 was found 
between cells grown in CS-FBS (Figure 4), whereas the difference between cells grown 
in FBS was less prominent and statistically nonsignificant. 
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Figure 3. A scheme, depicting the role of PKCε in signaling through receptor tyrosine kinases and the 
possible effects of MEK1 inhibition. 
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Figure 4. Growth of untreated ( ), and PD098059 treated ( ) cells in charcoal treated medium (CS-
FBS) and untreated ( ), and PD098059 treated ( ) cells in normal medium (FBS). Cell proliferation 
was measured by counting the total number of viable cells/plate by trypan blue exclusion using the 
hemacytometer. Data are the means of triplicate determinations in three independent experiments. 
 
 
PKCε is not sufficient to mediate the mitogenic signal downstream of PI3K. 
PKCε has been implicated in signaling via PI3K pathway, as a downstream mediator 
of mitogenic effects of PI3K. In order to determine whether overexpression of PKCε 
is sufficient in overcoming the effects of PI3K inhibition, LNWa and LNV cells were 
treated with LY294002, a specific inhibitor of PI3K, and then proliferation was 
analyzed using [3H]Thymidine  incorporation assay. No difference was observed 
between proliferation of PKCε – overexpressing cells and vector control (Fig. 5). 
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Figure 5. Proliferation of LNVa ( ), and LNWa ( ) cells treated with increasing doses of LY294002 . 
Cell proliferation was measured by [3H]Thymidine  incorporation in scintillation counter. Data are the 
means of triplicate measurements. 
 
 
Discussion. 
 
The major finding of the study was that PKCε is an oncogenic protein with the 
potential to induce androgen-independent growth of LNCaP tumors in both intact and 
castrated animals. These gene transfer experiments demonstrate that PKCε 
overexpression transforms LNCaP cells into androgen-idependent tumor cells that 
recapitulate many hallmark features of recurrent prostate cancer. The overexpression 
of PKCε leads to an uncontrolled and accelerated proliferation of LNCaP cells. The 
analysis also revealed that PKCε potentiates androgen independence, at least partially, 
through the MAP kinase pathway, most probably via Raf -1 activation. Although 
there is solid evidence that Raf-1 is a downstream target of PKCε, Ras/Raf induction 
alone is insufficient to promote the androgen-independent proliferation of LNCaP 
cells (21-22). Therefore, PKCε must signal to additional downstream targets to 
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overcome the growth-regulatory signals that normally control the cell cycle 
progression of LNCaP cells. Although PI3K pathway is a major survival pathway of 
LNCaP cells, PKCε does not seem to be implicated in a downstream signaling of 
PI3K, promoting proliferation.  
 
It is of note that multiple oncoproteins, and PKC isozymes, have been  overexpressed 
in LNCaP cells without producing the phenotype of LNW cells. Although many 
important issues need to be further investigated, this study demonstrates that PKCε 
may play an important role in the progression to androgen independence in human 
prostate cancers.   
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